CA2475113C - Isothiazole derivatives useful as anticancer agents - Google Patents
Isothiazole derivatives useful as anticancer agents Download PDFInfo
- Publication number
- CA2475113C CA2475113C CA002475113A CA2475113A CA2475113C CA 2475113 C CA2475113 C CA 2475113C CA 002475113 A CA002475113 A CA 002475113A CA 2475113 A CA2475113 A CA 2475113A CA 2475113 C CA2475113 C CA 2475113C
- Authority
- CA
- Canada
- Prior art keywords
- carboxylic acid
- acid amide
- isothiazole
- ureido
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002246 antineoplastic agent Substances 0.000 title description 4
- 150000003854 isothiazoles Chemical class 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 241
- 125000000623 heterocyclic group Chemical group 0.000 claims description 35
- 125000003118 aryl group Chemical group 0.000 claims description 29
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- 125000004122 cyclic group Chemical group 0.000 claims description 14
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 14
- 229910052717 sulfur Inorganic materials 0.000 claims description 14
- 125000004434 sulfur atom Chemical group 0.000 claims description 14
- 125000001424 substituent group Chemical group 0.000 claims description 11
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 125000005842 heteroatom Chemical group 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- ZBGPVZIUOBZFOK-UHFFFAOYSA-N (2,6-difluoro-4-methylphenyl)methanol Chemical compound CC1=CC(F)=C(CO)C(F)=C1 ZBGPVZIUOBZFOK-UHFFFAOYSA-N 0.000 claims description 6
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 6
- KLHRZAAZABAKME-UHFFFAOYSA-N (3-chloro-2,6-difluorophenyl)methanol Chemical compound OCC1=C(F)C=CC(Cl)=C1F KLHRZAAZABAKME-UHFFFAOYSA-N 0.000 claims description 4
- OJCKRUXYQDIIES-UHFFFAOYSA-N (4-chloro-2,6-difluorophenyl)methanol Chemical compound OCC1=C(F)C=C(Cl)C=C1F OJCKRUXYQDIIES-UHFFFAOYSA-N 0.000 claims description 4
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- DMPWHQMAGPTBSL-UHFFFAOYSA-N (2,3,6-trifluoro-4-methylphenyl)methanol Chemical compound CC1=CC(F)=C(CO)C(F)=C1F DMPWHQMAGPTBSL-UHFFFAOYSA-N 0.000 claims description 3
- ZHKDUZIFNFQCPE-UHFFFAOYSA-N (4-chloro-2,3,6-trifluorophenyl)methanol Chemical compound OCC1=C(F)C=C(Cl)C(F)=C1F ZHKDUZIFNFQCPE-UHFFFAOYSA-N 0.000 claims description 3
- CJGOKVYRNUALRJ-UHFFFAOYSA-N (4-bromo-2,3,6-trifluorophenyl)methanol Chemical compound OCC1=C(F)C=C(Br)C(F)=C1F CJGOKVYRNUALRJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 9
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 2
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 229910006069 SO3H Inorganic materials 0.000 claims 1
- -1 isothiazole derivative compounds Chemical class 0.000 abstract description 92
- 238000002360 preparation method Methods 0.000 abstract description 12
- 239000000203 mixture Substances 0.000 description 106
- 238000000034 method Methods 0.000 description 96
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 94
- PCXTYKGTWQCNJI-UHFFFAOYSA-N 1,2-thiazole-4-carboxylic acid Chemical compound OC(=O)C=1C=NSC=1 PCXTYKGTWQCNJI-UHFFFAOYSA-N 0.000 description 80
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 75
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 70
- 238000005481 NMR spectroscopy Methods 0.000 description 69
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 68
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 65
- 239000000243 solution Substances 0.000 description 60
- 239000007787 solid Substances 0.000 description 55
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 50
- 150000001408 amides Chemical class 0.000 description 45
- 150000003839 salts Chemical class 0.000 description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 38
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 35
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 35
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 31
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 30
- 239000012044 organic layer Substances 0.000 description 29
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 28
- 206010028980 Neoplasm Diseases 0.000 description 27
- BEPMYBTTZSNHPS-UHFFFAOYSA-N 1,2-thiazole-4-carboxamide Chemical compound NC(=O)C=1C=NSC=1 BEPMYBTTZSNHPS-UHFFFAOYSA-N 0.000 description 25
- 238000003756 stirring Methods 0.000 description 24
- 239000002253 acid Substances 0.000 description 22
- 239000011734 sodium Substances 0.000 description 22
- 238000004128 high performance liquid chromatography Methods 0.000 description 21
- 239000002585 base Substances 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 18
- 241000124008 Mammalia Species 0.000 description 17
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 17
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 16
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 229910052708 sodium Inorganic materials 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 13
- 229910052799 carbon Inorganic materials 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 239000010410 layer Substances 0.000 description 13
- 239000008194 pharmaceutical composition Substances 0.000 description 13
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 13
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 12
- 229940002612 prodrug Drugs 0.000 description 11
- 239000000651 prodrug Substances 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 10
- 239000012442 inert solvent Substances 0.000 description 10
- 239000012267 brine Substances 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 125000004501 isothiazol-5-yl group Chemical group S1N=CC=C1* 0.000 description 8
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- LUGNUVHQIIOEJH-UHFFFAOYSA-N phenyl n-[4-carbamoyl-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]-1,2-thiazol-5-yl]carbamate Chemical compound FC1=C(F)C(C)=CC(F)=C1COC1=NSC(NC(=O)OC=2C=CC=CC=2)=C1C(N)=O LUGNUVHQIIOEJH-UHFFFAOYSA-N 0.000 description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 7
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 7
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 7
- 239000004202 carbamide Substances 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 7
- 239000002798 polar solvent Substances 0.000 description 7
- 210000002307 prostate Anatomy 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 150000002148 esters Chemical group 0.000 description 6
- 230000003463 hyperproliferative effect Effects 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 5
- 102000052567 Anaphase-Promoting Complex-Cyclosome Apc1 Subunit Human genes 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 201000004681 Psoriasis Diseases 0.000 description 5
- 108091006463 SLC25A24 Proteins 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 235000013877 carbamide Nutrition 0.000 description 5
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical class CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 5
- 230000036571 hydration Effects 0.000 description 5
- 238000006703 hydration reaction Methods 0.000 description 5
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000002611 ovarian Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000011593 sulfur Substances 0.000 description 5
- RGUABPVONIGVAT-UHFFFAOYSA-N 3-(4-methylpiperazin-1-yl)propan-1-amine Chemical compound CN1CCN(CCCN)CC1 RGUABPVONIGVAT-UHFFFAOYSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 4
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 4
- 235000019445 benzyl alcohol Nutrition 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 4
- 150000007522 mineralic acids Chemical class 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- SYGTUWWBOUMVHV-UHFFFAOYSA-N phenyl n-[4-carbamoyl-3-[(2,5-difluoro-4-methylphenyl)methoxy]-1,2-thiazol-5-yl]carbamate Chemical compound C1=C(F)C(C)=CC(F)=C1COC1=NSC(NC(=O)OC=2C=CC=CC=2)=C1C(N)=O SYGTUWWBOUMVHV-UHFFFAOYSA-N 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 4
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000002390 rotary evaporation Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000001665 trituration Methods 0.000 description 4
- JGIXSUUXGXJGDM-UHFFFAOYSA-N (4-chloro-2,5-difluorophenyl)methanol Chemical compound OCC1=CC(F)=C(Cl)C=C1F JGIXSUUXGXJGDM-UHFFFAOYSA-N 0.000 description 3
- JWBCGELUZPPPNB-UHFFFAOYSA-N (4-methoxyphenyl)methyl 2-cyanoethanimidothioate Chemical compound COC1=CC=C(CSC(=N)CC#N)C=C1 JWBCGELUZPPPNB-UHFFFAOYSA-N 0.000 description 3
- IGPZTDFMRFYKGY-UHFFFAOYSA-N 2-(aminomethyl)morpholine-4-carboxylic acid Chemical compound NCC1CN(C(O)=O)CCO1 IGPZTDFMRFYKGY-UHFFFAOYSA-N 0.000 description 3
- VPBWZBGZWHDNKL-UHFFFAOYSA-N 3-pyrrolidin-1-ylpropan-1-amine Chemical compound NCCCN1CCCC1 VPBWZBGZWHDNKL-UHFFFAOYSA-N 0.000 description 3
- GTTVSBCPMJQRSP-UHFFFAOYSA-N 4-chloro-2,6-difluorobenzaldehyde Chemical compound FC1=CC(Cl)=CC(F)=C1C=O GTTVSBCPMJQRSP-UHFFFAOYSA-N 0.000 description 3
- LSDYCEIPEBJKPT-UHFFFAOYSA-N 4-pyrrolidin-1-ylbutan-1-amine Chemical compound NCCCCN1CCCC1 LSDYCEIPEBJKPT-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 description 3
- 208000032612 Glial tumor Diseases 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 3
- 229960004217 benzyl alcohol Drugs 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012039 electrophile Substances 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 201000011066 hemangioma Diseases 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- XBPAJDWNIXPXFJ-UHFFFAOYSA-N n'-propan-2-ylpentane-1,5-diamine Chemical compound CC(C)NCCCCCN XBPAJDWNIXPXFJ-UHFFFAOYSA-N 0.000 description 3
- WHRJQEJFHCRDIM-UHFFFAOYSA-M n-(4-cyano-3-sulfanylidene-1,2-thiazol-5-yl)-1-ethoxymethanimidate Chemical compound CCOC(=O)NC=1SN=C([S-])C=1C#N WHRJQEJFHCRDIM-UHFFFAOYSA-M 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 description 3
- DJXGJYCSPXRZAK-UHFFFAOYSA-N phenyl n-(sulfanylidenemethylidene)carbamate Chemical compound S=C=NC(=O)OC1=CC=CC=C1 DJXGJYCSPXRZAK-UHFFFAOYSA-N 0.000 description 3
- HEQLLJSEFFOOCM-UHFFFAOYSA-N phenyl n-[4-carbamoyl-3-[(2,6-difluoro-4-methylphenyl)methoxy]-1,2-thiazol-5-yl]carbamate Chemical compound FC1=CC(C)=CC(F)=C1COC1=NSC(NC(=O)OC=2C=CC=CC=2)=C1C(N)=O HEQLLJSEFFOOCM-UHFFFAOYSA-N 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 230000004862 vasculogenesis Effects 0.000 description 3
- OAFXZKIFYIAVLA-UHFFFAOYSA-N (2,5-difluoro-4-methylphenyl)methanol Chemical compound CC1=CC(F)=C(CO)C=C1F OAFXZKIFYIAVLA-UHFFFAOYSA-N 0.000 description 2
- PTDVPWWJRCOIIO-UHFFFAOYSA-N (4-methoxyphenyl)methanethiol Chemical compound COC1=CC=C(CS)C=C1 PTDVPWWJRCOIIO-UHFFFAOYSA-N 0.000 description 2
- YISYUYYETHYYMD-UHFFFAOYSA-N 1,3-difluoro-5-methylbenzene Chemical compound CC1=CC(F)=CC(F)=C1 YISYUYYETHYYMD-UHFFFAOYSA-N 0.000 description 2
- DABSRRDPYUORCO-UHFFFAOYSA-N 1-(4-aminobutyl)pyrrolidine-3,4-diol Chemical compound NCCCCN1CC(O)C(O)C1 DABSRRDPYUORCO-UHFFFAOYSA-N 0.000 description 2
- JMHLNNPYJXOBRI-UHFFFAOYSA-N 1-amino-5-pyrrolidin-1-ylpentan-3-ol Chemical compound NCCC(O)CCN1CCCC1 JMHLNNPYJXOBRI-UHFFFAOYSA-N 0.000 description 2
- DZTNEQVEYQORQO-UHFFFAOYSA-N 1-bromo-2,5-difluoro-4-methylbenzene Chemical compound CC1=CC(F)=C(Br)C=C1F DZTNEQVEYQORQO-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
- GRMIRMGOHHMAGB-UHFFFAOYSA-N 3-(2,2-dicyano-1-sulfanylethenyl)-1,1-dimethylurea Chemical compound CN(C)C(=O)NC(S)=C(C#N)C#N GRMIRMGOHHMAGB-UHFFFAOYSA-N 0.000 description 2
- NJQGDEVXWKUKSI-UHFFFAOYSA-N 3-(4-cyano-3-hexylsulfanyl-1,2-thiazol-5-yl)-1,1-dimethylurea Chemical compound CCCCCCSC1=NSC(NC(=O)N(C)C)=C1C#N NJQGDEVXWKUKSI-UHFFFAOYSA-N 0.000 description 2
- ZQMFJMRCBGOLED-UHFFFAOYSA-N 3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-[4-(3,4-dihydroxypyrrolidin-1-yl)butylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound C1=C(F)C(C)=CC(F)=C1COC1=NSC(NC(=O)NCCCCN2CC(O)C(O)C2)=C1C(N)=O ZQMFJMRCBGOLED-UHFFFAOYSA-N 0.000 description 2
- QIMZMNAVSSZUFG-UHFFFAOYSA-N 3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-[6-(dimethylamino)hexylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NCCCCCCN(C)C)SN=C1OCC1=CC(F)=C(C)C=C1F QIMZMNAVSSZUFG-UHFFFAOYSA-N 0.000 description 2
- KAAIVUBEOYDTPN-UHFFFAOYSA-N 3-[(2,6-difluoro-4-methylphenyl)methoxy]-5-[(4-hydroxy-5-piperidin-1-ylpentyl)carbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound FC1=CC(C)=CC(F)=C1COC1=NSC(NC(=O)NCCCC(O)CN2CCCCC2)=C1C(N)=O KAAIVUBEOYDTPN-UHFFFAOYSA-N 0.000 description 2
- ARMSUXIOUXKTQE-UHFFFAOYSA-N 3-[(2,6-difluoro-4-methylphenyl)methoxy]-5-[2-(1-methylpyrrolidin-2-yl)ethylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound CN1CCCC1CCNC(=O)NC1=C(C(N)=O)C(OCC=2C(=CC(C)=CC=2F)F)=NS1 ARMSUXIOUXKTQE-UHFFFAOYSA-N 0.000 description 2
- GVJSWBMFVKGXAE-UHFFFAOYSA-N 3-[(2,6-difluoro-4-methylphenyl)methoxy]-5-[3-(dimethylamino)propylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NCCCN(C)C)SN=C1OCC1=C(F)C=C(C)C=C1F GVJSWBMFVKGXAE-UHFFFAOYSA-N 0.000 description 2
- KOZFIMSVPMYVSF-UHFFFAOYSA-N 3-[(2,6-difluoro-4-methylphenyl)methoxy]-5-[4-(dimethylamino)butylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NCCCCN(C)C)SN=C1OCC1=C(F)C=C(C)C=C1F KOZFIMSVPMYVSF-UHFFFAOYSA-N 0.000 description 2
- QALOCKWTTHFIOR-UHFFFAOYSA-N 3-[(2-fluoro-4-methylphenyl)methoxy]-5-[5-[4-(2-hydroxyethyl)piperazin-1-yl]pentylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound FC1=CC(C)=CC=C1COC1=NSC(NC(=O)NCCCCCN2CCN(CCO)CC2)=C1C(N)=O QALOCKWTTHFIOR-UHFFFAOYSA-N 0.000 description 2
- HXHAJRMTJXHJJZ-UHFFFAOYSA-N 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-(4-pyrrolidin-1-ylbutylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound S1N=C(OCC=2C(=CC(Br)=CC=2F)F)C(C(=O)N)=C1NC(=O)NCCCCN1CCCC1 HXHAJRMTJXHJJZ-UHFFFAOYSA-N 0.000 description 2
- HNXQEZKWSACNSO-UHFFFAOYSA-N 3-[(4-bromo-2-fluorophenyl)methoxy]-5-(2-hydroxypropylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NCC(O)C)SN=C1OCC1=CC=C(Br)C=C1F HNXQEZKWSACNSO-UHFFFAOYSA-N 0.000 description 2
- KBASJCBTQBVBOG-UHFFFAOYSA-N 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-(4-pyrrolidin-1-ylbutylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound S1N=C(OCC=2C(=CC(Cl)=CC=2F)F)C(C(=O)N)=C1NC(=O)NCCCCN1CCCC1 KBASJCBTQBVBOG-UHFFFAOYSA-N 0.000 description 2
- DRGDSJISDZPWDP-UHFFFAOYSA-N 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-[(3-hydroxy-5-pyrrolidin-1-ylpentyl)carbamoylamino]-1,2-thiazole-4-carboxamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.N=1SC(NC(=O)NCCC(O)CCN2CCCC2)=C(C(=O)N)C=1OCC1=C(F)C=C(Cl)C=C1F DRGDSJISDZPWDP-UHFFFAOYSA-N 0.000 description 2
- PNLQTLDEFBVYHM-UHFFFAOYSA-N 5-(4-pyrrolidin-1-ylbutylcarbamoylamino)-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]-1,2-thiazole-4-carboxamide Chemical compound FC1=C(F)C(C)=CC(F)=C1COC1=NSC(NC(=O)NCCCCN2CCCC2)=C1C(N)=O PNLQTLDEFBVYHM-UHFFFAOYSA-N 0.000 description 2
- RXMRAXREFDBQOO-UHFFFAOYSA-N 5-(dimethylcarbamoylamino)-3-heptoxy-1,2-thiazole-4-carboxamide Chemical compound CCCCCCCOC1=NSC(NC(=O)N(C)C)=C1C(N)=O RXMRAXREFDBQOO-UHFFFAOYSA-N 0.000 description 2
- MUMZOQWBQONBKS-UHFFFAOYSA-N 5-(methylcarbamoylamino)-3-propylsulfanyl-1,2-thiazole-4-carboxamide Chemical compound CCCSC1=NSC(NC(=O)NC)=C1C(N)=O MUMZOQWBQONBKS-UHFFFAOYSA-N 0.000 description 2
- OPKHOMGGMCLBCP-UHFFFAOYSA-N 5-[3-(4-methylpiperazin-1-yl)propylcarbamoylamino]-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]-1,2-thiazole-4-carboxamide Chemical compound C1CN(C)CCN1CCCNC(=O)NC1=C(C(N)=O)C(OCC=2C(=C(F)C(C)=CC=2F)F)=NS1 OPKHOMGGMCLBCP-UHFFFAOYSA-N 0.000 description 2
- KDDHCJASWHEZMD-UHFFFAOYSA-N 5-[[4-(tert-butylamino)-3-hydroxybutyl]carbamoylamino]-3-[(2,5-difluoro-4-methylphenyl)methoxy]-1,2-thiazole-4-carboxamide Chemical compound C1=C(F)C(C)=CC(F)=C1COC1=NSC(NC(=O)NCCC(O)CNC(C)(C)C)=C1C(N)=O KDDHCJASWHEZMD-UHFFFAOYSA-N 0.000 description 2
- BNUVYIYIDYDOHD-UHFFFAOYSA-N 5-amino-1-piperidin-1-ylpentan-2-ol Chemical compound NCCCC(O)CN1CCCCC1 BNUVYIYIDYDOHD-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- JYNULGNVGXIUJP-UHFFFAOYSA-N C=1C=CC=CC=1COC(=N)C(C#N)=C(S)NC(=O)OC1=CC=CC=C1 Chemical compound C=1C=CC=CC=1COC(=N)C(C#N)=C(S)NC(=O)OC1=CC=CC=C1 JYNULGNVGXIUJP-UHFFFAOYSA-N 0.000 description 2
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 101100458361 Drosophila melanogaster SmydA-8 gene Proteins 0.000 description 2
- 241001340534 Eido Species 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000004703 alkoxides Chemical class 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 150000001351 alkyl iodides Chemical class 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000002280 anti-androgenic effect Effects 0.000 description 2
- 230000003388 anti-hormonal effect Effects 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000000051 antiandrogen Substances 0.000 description 2
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000001109 blastomere Anatomy 0.000 description 2
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 2
- 229910052792 caesium Inorganic materials 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000460 chlorine Chemical group 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical compound CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- JHMUVDDIPKDNGB-UHFFFAOYSA-N ethyl n-(4-cyano-3-pentylsulfanyl-1,2-thiazol-5-yl)carbamate Chemical compound CCCCCSC1=NSC(NC(=O)OCC)=C1C#N JHMUVDDIPKDNGB-UHFFFAOYSA-N 0.000 description 2
- BDTDECDAHYOJRO-UHFFFAOYSA-N ethyl n-(sulfanylidenemethylidene)carbamate Chemical compound CCOC(=O)N=C=S BDTDECDAHYOJRO-UHFFFAOYSA-N 0.000 description 2
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000012444 intercalating antibiotic Substances 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BRMYZIKAHFEUFJ-UHFFFAOYSA-L mercury diacetate Chemical compound CC(=O)O[Hg]OC(C)=O BRMYZIKAHFEUFJ-UHFFFAOYSA-L 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 230000000394 mitotic effect Effects 0.000 description 2
- JILXUIANNUALRZ-UHFFFAOYSA-N n',n'-diethylbutane-1,4-diamine Chemical compound CCN(CC)CCCCN JILXUIANNUALRZ-UHFFFAOYSA-N 0.000 description 2
- GCOWZPRIMFGIDQ-UHFFFAOYSA-N n',n'-dimethylbutane-1,4-diamine Chemical compound CN(C)CCCCN GCOWZPRIMFGIDQ-UHFFFAOYSA-N 0.000 description 2
- QHJABUZHRJTCAR-UHFFFAOYSA-N n'-methylpropane-1,3-diamine Chemical compound CNCCCN QHJABUZHRJTCAR-UHFFFAOYSA-N 0.000 description 2
- ZTHRQJQJODGZHV-UHFFFAOYSA-N n-phenylpropanamide Chemical compound CCC(=O)NC1=CC=CC=C1 ZTHRQJQJODGZHV-UHFFFAOYSA-N 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 2
- VECIRMAUENXXMG-UHFFFAOYSA-N phenyl n-(4-carbamoyl-3-sulfanylidene-1,2-thiazol-5-yl)carbamate Chemical compound SC1=NSC(NC(=O)OC=2C=CC=CC=2)=C1C(=O)N VECIRMAUENXXMG-UHFFFAOYSA-N 0.000 description 2
- KPQVAANLSAIRSI-UHFFFAOYSA-N phenyl n-[4-carbamoyl-3-[(4-chloro-2,6-difluorophenyl)methoxy]-1,2-thiazol-5-yl]carbamate Chemical compound N=1SC(NC(=O)OC=2C=CC=CC=2)=C(C(=O)N)C=1OCC1=C(F)C=C(Cl)C=C1F KPQVAANLSAIRSI-UHFFFAOYSA-N 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 239000003880 polar aprotic solvent Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 159000000001 potassium salts Chemical class 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 229940116357 potassium thiocyanate Drugs 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000005747 tumor angiogenesis Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- DQSLGRQGXKEAKS-UHFFFAOYSA-N (2,3-difluoro-4-methylphenyl)methanol Chemical compound CC1=CC=C(CO)C(F)=C1F DQSLGRQGXKEAKS-UHFFFAOYSA-N 0.000 description 1
- NFEMQPHLTXHHBH-UHFFFAOYSA-N (2-fluoro-4,6-dimethylphenyl)methanol Chemical compound CC1=CC(C)=C(CO)C(F)=C1 NFEMQPHLTXHHBH-UHFFFAOYSA-N 0.000 description 1
- SKAOZSHXPPIGPZ-MRVPVSSYSA-N (3r)-1-(4-aminobutyl)pyrrolidin-3-ol Chemical compound NCCCCN1CC[C@@H](O)C1 SKAOZSHXPPIGPZ-MRVPVSSYSA-N 0.000 description 1
- LSRHFWSNUFIKER-UHFFFAOYSA-N (4-bromo-2,6-difluorophenyl)methanol Chemical compound OCC1=C(F)C=C(Br)C=C1F LSRHFWSNUFIKER-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- IDFPQEHZYBXIFO-GFCCVEGCSA-N (R)-(4-fluoro-2-propylphenyl)-(1H-imidazol-2-yl)methanol Chemical compound CCCc1cc(F)ccc1[C@@H](O)c1ncc[nH]1 IDFPQEHZYBXIFO-GFCCVEGCSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- LCCFNNNRUIJJBM-UHFFFAOYSA-N 1,1-dimethyl-3-(sulfanylidenemethylidene)urea Chemical compound CN(C)C(=O)N=C=S LCCFNNNRUIJJBM-UHFFFAOYSA-N 0.000 description 1
- YBBLOADPFWKNGS-UHFFFAOYSA-N 1,1-dimethylurea Chemical compound CN(C)C(N)=O YBBLOADPFWKNGS-UHFFFAOYSA-N 0.000 description 1
- ZQWBCGBMUFLFPC-UHFFFAOYSA-N 1,2,5-trifluoro-3-methylbenzene Chemical compound CC1=CC(F)=CC(F)=C1F ZQWBCGBMUFLFPC-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- ZMPIYDWJVKEYMM-UHFFFAOYSA-N 1-(3-chlorophenyl)-N-fluoromethanamine Chemical compound FNCC1=CC(=CC=C1)Cl ZMPIYDWJVKEYMM-UHFFFAOYSA-N 0.000 description 1
- QPMAEHBAXJSICW-UHFFFAOYSA-N 1-(bromomethyl)-2,3,5-trifluorobenzene Chemical compound FC1=CC(F)=C(F)C(CBr)=C1 QPMAEHBAXJSICW-UHFFFAOYSA-N 0.000 description 1
- KVSVNRFSKRFPIL-UHFFFAOYSA-N 1-(bromomethyl)-3,5-difluorobenzene Chemical compound FC1=CC(F)=CC(CBr)=C1 KVSVNRFSKRFPIL-UHFFFAOYSA-N 0.000 description 1
- DMHZDOTYAVHSEH-UHFFFAOYSA-N 1-(chloromethyl)-4-methylbenzene Chemical compound CC1=CC=C(CCl)C=C1 DMHZDOTYAVHSEH-UHFFFAOYSA-N 0.000 description 1
- SLFNGVGRINFJLK-UHFFFAOYSA-N 1-bromo-2-fluoro-4-methylbenzene Chemical compound CC1=CC=C(Br)C(F)=C1 SLFNGVGRINFJLK-UHFFFAOYSA-N 0.000 description 1
- JHLKSIOJYMGSMB-UHFFFAOYSA-N 1-bromo-3,5-difluorobenzene Chemical compound FC1=CC(F)=CC(Br)=C1 JHLKSIOJYMGSMB-UHFFFAOYSA-N 0.000 description 1
- AJCSNHQKXUSMMY-UHFFFAOYSA-N 1-chloro-2,4-difluorobenzene Chemical compound FC1=CC=C(Cl)C(F)=C1 AJCSNHQKXUSMMY-UHFFFAOYSA-N 0.000 description 1
- RFKBODCWHNDUTJ-UHFFFAOYSA-N 1-chloro-3,5-difluorobenzene Chemical compound FC1=CC(F)=CC(Cl)=C1 RFKBODCWHNDUTJ-UHFFFAOYSA-N 0.000 description 1
- NIOGDCDTKPQEAT-UHFFFAOYSA-N 1-chloro-4-fluoro-2-methylbenzene Chemical compound CC1=CC(F)=CC=C1Cl NIOGDCDTKPQEAT-UHFFFAOYSA-N 0.000 description 1
- RCWIWNUVHNAUQC-UHFFFAOYSA-N 1-fluoro-3,5-dimethylbenzene Chemical compound CC1=CC(C)=CC(F)=C1 RCWIWNUVHNAUQC-UHFFFAOYSA-N 0.000 description 1
- LMHCYRULPLGEEZ-UHFFFAOYSA-N 1-iodoheptane Chemical compound CCCCCCCI LMHCYRULPLGEEZ-UHFFFAOYSA-N 0.000 description 1
- ANOOTOPTCJRUPK-UHFFFAOYSA-N 1-iodohexane Chemical compound CCCCCCI ANOOTOPTCJRUPK-UHFFFAOYSA-N 0.000 description 1
- BLXSFCHWMBESKV-UHFFFAOYSA-N 1-iodopentane Chemical compound CCCCCI BLXSFCHWMBESKV-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- PNHGJPJOMCXSKN-UHFFFAOYSA-N 2-(1-methylpyrrolidin-2-yl)ethanamine Chemical compound CN1CCCC1CCN PNHGJPJOMCXSKN-UHFFFAOYSA-N 0.000 description 1
- TUKFFSGMQJSJQQ-UHFFFAOYSA-N 2-[4-(4-aminobutyl)piperazin-1-yl]ethanol Chemical compound NCCCCN1CCN(CCO)CC1 TUKFFSGMQJSJQQ-UHFFFAOYSA-N 0.000 description 1
- TZBOGCGZENWDHZ-UHFFFAOYSA-N 2-[4-(6-aminohexyl)piperazin-1-yl]ethanol Chemical compound NCCCCCCN1CCN(CCO)CC1 TZBOGCGZENWDHZ-UHFFFAOYSA-N 0.000 description 1
- GSCUXTICYWCTQP-UHFFFAOYSA-N 2-[4-aminobutyl(2-hydroxyethyl)amino]ethanol Chemical compound NCCCCN(CCO)CCO GSCUXTICYWCTQP-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical group CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- GBNVVYQYATZCAE-UHFFFAOYSA-N 3-(2-cyclohexylethoxy)-5-(dimethylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N(C)C)SN=C1OCCC1CCCCC1 GBNVVYQYATZCAE-UHFFFAOYSA-N 0.000 description 1
- VSFJANXTDBEJOG-UHFFFAOYSA-N 3-(3-methoxy-1,2-thiazol-5-yl)-1,1-dimethylurea Chemical compound CN(C(NC1=CC(=NS1)OC)=O)C VSFJANXTDBEJOG-UHFFFAOYSA-N 0.000 description 1
- JEFBJFRCEQEGMJ-UHFFFAOYSA-N 3-(4-chlorobutylsulfanyl)-5-(dimethylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound CN(C)C(=O)NC=1SN=C(SCCCCCl)C=1C(N)=O JEFBJFRCEQEGMJ-UHFFFAOYSA-N 0.000 description 1
- GXSVNWOYUAAJCT-UHFFFAOYSA-N 3-(4-cyano-3-sulfanylidene-1,2-thiazol-5-yl)-1,1-dimethylurea Chemical compound CN(C)C(=O)NC=1SN=C(S)C=1C#N GXSVNWOYUAAJCT-UHFFFAOYSA-N 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- FCWXRWVMSDNEOM-UHFFFAOYSA-N 3-[(2,3-dichloro-4-methylphenyl)methoxy]-5-[4-[4-(3-hydroxypropyl)piperazin-1-yl]butylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound ClC1=C(Cl)C(C)=CC=C1COC1=NSC(NC(=O)NCCCCN2CCN(CCCO)CC2)=C1C(N)=O FCWXRWVMSDNEOM-UHFFFAOYSA-N 0.000 description 1
- QSGIWSAWPWWCIC-UHFFFAOYSA-N 3-[(2,3-dichloro-4-methylphenyl)methoxy]-5-[5-[4-(2-hydroxyethyl)piperazin-1-yl]pentylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound ClC1=C(Cl)C(C)=CC=C1COC1=NSC(NC(=O)NCCCCCN2CCN(CCO)CC2)=C1C(N)=O QSGIWSAWPWWCIC-UHFFFAOYSA-N 0.000 description 1
- LDLLFNIFSBPNFS-UHFFFAOYSA-N 3-[(2,3-dichlorophenyl)methoxy]-5-[2-(1h-imidazol-5-yl)ethylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound N=1SC(NC(=O)NCCC=2N=CNC=2)=C(C(=O)N)C=1OCC1=CC=CC(Cl)=C1Cl LDLLFNIFSBPNFS-UHFFFAOYSA-N 0.000 description 1
- NCDDEQGXXIKLIS-UHFFFAOYSA-N 3-[(2,3-difluoro-4-methylphenyl)methoxy]-5-(3-morpholin-4-ylpropylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound FC1=C(F)C(C)=CC=C1COC1=NSC(NC(=O)NCCCN2CCOCC2)=C1C(N)=O NCDDEQGXXIKLIS-UHFFFAOYSA-N 0.000 description 1
- PBVVGXJTEXBPJR-UHFFFAOYSA-N 3-[(2,3-difluoro-4-methylphenyl)methoxy]-5-[3-(2-oxopyrrolidin-1-yl)propylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound FC1=C(F)C(C)=CC=C1COC1=NSC(NC(=O)NCCCN2C(CCC2)=O)=C1C(N)=O PBVVGXJTEXBPJR-UHFFFAOYSA-N 0.000 description 1
- QBVIYFHKKKDATC-UHFFFAOYSA-N 3-[(2,3-difluoro-4-methylphenyl)methoxy]-5-[4-(3,4-dihydroxypyrrolidin-1-yl)butylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound FC1=C(F)C(C)=CC=C1COC1=NSC(NC(=O)NCCCCN2CC(O)C(O)C2)=C1C(N)=O QBVIYFHKKKDATC-UHFFFAOYSA-N 0.000 description 1
- WGCXOIDXNWSKTK-UHFFFAOYSA-N 3-[(2,3-difluoro-4-methylphenyl)methoxy]-5-[4-[ethyl(2-hydroxyethyl)amino]butylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NCCCCN(CCO)CC)SN=C1OCC1=CC=C(C)C(F)=C1F WGCXOIDXNWSKTK-UHFFFAOYSA-N 0.000 description 1
- HYARLBBGZFHSQU-UHFFFAOYSA-N 3-[(2,4-difluorophenyl)methoxy]-5-(dimethylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N(C)C)SN=C1OCC1=CC=C(F)C=C1F HYARLBBGZFHSQU-UHFFFAOYSA-N 0.000 description 1
- JEVSCGBPIHGARR-UHFFFAOYSA-N 3-[(2,4-dimethylphenyl)methoxy]-5-(2-morpholin-4-ylethylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound CC1=CC(C)=CC=C1COC1=NSC(NC(=O)NCCN2CCOCC2)=C1C(N)=O JEVSCGBPIHGARR-UHFFFAOYSA-N 0.000 description 1
- IBFNUAZEHGFIHS-UHFFFAOYSA-N 3-[(2,4-dimethylphenyl)methoxy]-5-(4-morpholin-4-ylbutylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound CC1=CC(C)=CC=C1COC1=NSC(NC(=O)NCCCCN2CCOCC2)=C1C(N)=O IBFNUAZEHGFIHS-UHFFFAOYSA-N 0.000 description 1
- CPRKLUBVBPWLTQ-UHFFFAOYSA-N 3-[(2,5-dichlorophenyl)methoxy]-5-[6-(dimethylamino)hexylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NCCCCCCN(C)C)SN=C1OCC1=CC(Cl)=CC=C1Cl CPRKLUBVBPWLTQ-UHFFFAOYSA-N 0.000 description 1
- PJTJKGLWYNGGML-UHFFFAOYSA-N 3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-(3-imidazol-1-ylpropylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound C1=C(F)C(C)=CC(F)=C1COC1=NSC(NC(=O)NCCCN2C=NC=C2)=C1C(N)=O PJTJKGLWYNGGML-UHFFFAOYSA-N 0.000 description 1
- KKBIMILSPHAXSQ-UHFFFAOYSA-N 3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-(4-pyrrolidin-1-ylbutylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound C1=C(F)C(C)=CC(F)=C1COC1=NSC(NC(=O)NCCCCN2CCCC2)=C1C(N)=O KKBIMILSPHAXSQ-UHFFFAOYSA-N 0.000 description 1
- MPTCPZWCESFTRV-UHFFFAOYSA-N 3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-[(6-hydroxy-7-piperidin-1-ylheptyl)carbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound C1=C(F)C(C)=CC(F)=C1COC1=NSC(NC(=O)NCCCCCC(O)CN2CCCCC2)=C1C(N)=O MPTCPZWCESFTRV-UHFFFAOYSA-N 0.000 description 1
- BNOBRNDZUJWRCU-UHFFFAOYSA-N 3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-[2-(1h-imidazol-5-yl)ethylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound C1=C(F)C(C)=CC(F)=C1COC1=NSC(NC(=O)NCCC=2N=CNC=2)=C1C(N)=O BNOBRNDZUJWRCU-UHFFFAOYSA-N 0.000 description 1
- GRIBVKFHFTZOCK-UHFFFAOYSA-N 3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-[4-(3-hydroxypyrrolidin-1-yl)butylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound C1=C(F)C(C)=CC(F)=C1COC1=NSC(NC(=O)NCCCCN2CC(O)CC2)=C1C(N)=O GRIBVKFHFTZOCK-UHFFFAOYSA-N 0.000 description 1
- WKCLDWBEDQOPTO-UHFFFAOYSA-N 3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-[4-[2-(hydroxymethyl)pyrrolidin-1-yl]butylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound C1=C(F)C(C)=CC(F)=C1COC1=NSC(NC(=O)NCCCCN2C(CCC2)CO)=C1C(N)=O WKCLDWBEDQOPTO-UHFFFAOYSA-N 0.000 description 1
- JGVUZSYKCBQTGT-UHFFFAOYSA-N 3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-[4-[ethyl(2-hydroxyethyl)amino]butylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NCCCCN(CCO)CC)SN=C1OCC1=CC(F)=C(C)C=C1F JGVUZSYKCBQTGT-UHFFFAOYSA-N 0.000 description 1
- QCLVAVONOBHJNH-UHFFFAOYSA-N 3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-[[3-(2,6-dimethylmorpholin-4-yl)-2-methylpropyl]carbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound C1C(C)OC(C)CN1CC(C)CNC(=O)NC(=C1C(N)=O)SN=C1OCC1=CC(F)=C(C)C=C1F QCLVAVONOBHJNH-UHFFFAOYSA-N 0.000 description 1
- STRFYTRBCAAEGQ-UHFFFAOYSA-N 3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-[[4-(3-hydroxypiperidin-1-yl)butyl-methylcarbamoyl]amino]-1,2-thiazole-4-carboxamide Chemical compound S1N=C(OCC=2C(=CC(C)=C(F)C=2)F)C(C(N)=O)=C1NC(=O)N(C)CCCCN1CCCC(O)C1 STRFYTRBCAAEGQ-UHFFFAOYSA-N 0.000 description 1
- NXJIZBSCGACCRO-UHFFFAOYSA-N 3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-[[5-hydroxy-6-(2-methylpropylamino)hexyl]carbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NCCCCC(O)CNCC(C)C)SN=C1OCC1=CC(F)=C(C)C=C1F NXJIZBSCGACCRO-UHFFFAOYSA-N 0.000 description 1
- GVBPIICJDJFVFO-UHFFFAOYSA-N 3-[(2,5-difluoro-4-methylphenyl)methoxy]-5-[[ethyl-[3-(4-methylpiperazin-1-yl)propyl]carbamoyl]amino]-1,2-thiazole-4-carboxamide Chemical compound S1N=C(OCC=2C(=CC(C)=C(F)C=2)F)C(C(N)=O)=C1NC(=O)N(CC)CCCN1CCN(C)CC1 GVBPIICJDJFVFO-UHFFFAOYSA-N 0.000 description 1
- RUGCEQIMVCGXJI-UHFFFAOYSA-N 3-[(2,6-difluoro-4-methylphenyl)methoxy]-5-(2-methylpropylcarbamoylamino)-1,2-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=C(NC(=O)NCC(C)C)SN=C1OCC1=C(F)C=C(C)C=C1F RUGCEQIMVCGXJI-UHFFFAOYSA-N 0.000 description 1
- RNAZNZTVDAAXMA-UHFFFAOYSA-N 3-[(2,6-difluoro-4-methylphenyl)methoxy]-5-(methylcarbamoylamino)-1,2-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=C(NC(=O)NC)SN=C1OCC1=C(F)C=C(C)C=C1F RNAZNZTVDAAXMA-UHFFFAOYSA-N 0.000 description 1
- RDWLAZKXPUAJLU-UHFFFAOYSA-N 3-[(2,6-difluoro-4-methylphenyl)methoxy]-5-[(3-hydroxy-5-pyrrolidin-1-ylpentyl)carbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound FC1=CC(C)=CC(F)=C1COC1=NSC(NC(=O)NCCC(O)CCN2CCCC2)=C1C(N)=O RDWLAZKXPUAJLU-UHFFFAOYSA-N 0.000 description 1
- UYARZCXWNDBEAI-UHFFFAOYSA-N 3-[(2,6-difluoro-4-methylphenyl)methoxy]-5-[3-(4-methylpiperazin-1-yl)propylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound C1CN(C)CCN1CCCNC(=O)NC1=C(C(N)=O)C(OCC=2C(=CC(C)=CC=2F)F)=NS1 UYARZCXWNDBEAI-UHFFFAOYSA-N 0.000 description 1
- XYTCWWNCWZVDGK-UHFFFAOYSA-N 3-[(2,6-difluoro-4-methylphenyl)methoxy]-5-[[7-(dimethylamino)-6-hydroxyheptyl]carbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NCCCCCC(O)CN(C)C)SN=C1OCC1=C(F)C=C(C)C=C1F XYTCWWNCWZVDGK-UHFFFAOYSA-N 0.000 description 1
- CPWVQCVUJKICFE-UHFFFAOYSA-N 3-[(2-chlorophenyl)methylsulfanyl]-5-(dimethylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N(C)C)SN=C1SCC1=CC=CC=C1Cl CPWVQCVUJKICFE-UHFFFAOYSA-N 0.000 description 1
- VZCRCWHXADPFSF-UHFFFAOYSA-N 3-[(2-fluoro-3-methylphenyl)methoxy]-5-(2-methylpropylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NCC(C)C)SN=C1OCC1=CC=CC(C)=C1F VZCRCWHXADPFSF-UHFFFAOYSA-N 0.000 description 1
- KEMYKPKZAIQAMD-UHFFFAOYSA-N 3-[(2-fluoro-4,6-dimethylphenyl)methoxy]-5-[(2-hydroxy-3-morpholin-4-ylpropyl)carbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound FC1=CC(C)=CC(C)=C1COC1=NSC(NC(=O)NCC(O)CN2CCOCC2)=C1C(N)=O KEMYKPKZAIQAMD-UHFFFAOYSA-N 0.000 description 1
- MXCPAUXJQZSJJQ-UHFFFAOYSA-N 3-[(2-fluoro-4-methylphenyl)methoxy]-5-(2-hydroxypropylcarbamoylamino)-2h-1,2-thiazole-3-carboxamide Chemical compound N1SC(NC(=O)NCC(O)C)=CC1(C(N)=O)OCC1=CC=C(C)C=C1F MXCPAUXJQZSJJQ-UHFFFAOYSA-N 0.000 description 1
- JUCFNHRHVPGVEX-UHFFFAOYSA-N 3-[(2-fluoro-4-methylphenyl)methoxy]-5-(2-pyrrolidin-1-ylethylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound FC1=CC(C)=CC=C1COC1=NSC(NC(=O)NCCN2CCCC2)=C1C(N)=O JUCFNHRHVPGVEX-UHFFFAOYSA-N 0.000 description 1
- AMLIAESKGXHWSE-UHFFFAOYSA-N 3-[(2-fluoro-4-methylphenyl)methoxy]-5-[5-(propan-2-ylamino)pentylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NCCCCCNC(C)C)SN=C1OCC1=CC=C(C)C=C1F AMLIAESKGXHWSE-UHFFFAOYSA-N 0.000 description 1
- YQHCXVXYLZJZEQ-UHFFFAOYSA-N 3-[(2-fluoro-4-methylphenyl)methoxy]-5-[6-[4-(2-hydroxyethyl)piperazin-1-yl]hexylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound FC1=CC(C)=CC=C1COC1=NSC(NC(=O)NCCCCCCN2CCN(CCO)CC2)=C1C(N)=O YQHCXVXYLZJZEQ-UHFFFAOYSA-N 0.000 description 1
- GEADPPQCPPUOQM-UHFFFAOYSA-N 3-[(2-fluoro-4-methylphenyl)methoxy]-5-[[4-hydroxy-5-(2-methylpropylamino)pentyl]carbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NCCCC(O)CNCC(C)C)SN=C1OCC1=CC=C(C)C=C1F GEADPPQCPPUOQM-UHFFFAOYSA-N 0.000 description 1
- JVKNSQCJIAXQDX-UHFFFAOYSA-N 3-[(2-fluorophenyl)methylsulfanyl]-5-(2-methylpropylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NCC(C)C)SN=C1SCC1=CC=CC=C1F JVKNSQCJIAXQDX-UHFFFAOYSA-N 0.000 description 1
- QHUXFKVUQAZIBU-UHFFFAOYSA-N 3-[(2-fluorophenyl)methylsulfanyl]-5-(3-pyrrolidin-1-ylpropylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound N=1SC(NC(=O)NCCCN2CCCC2)=C(C(=O)N)C=1SCC1=CC=CC=C1F QHUXFKVUQAZIBU-UHFFFAOYSA-N 0.000 description 1
- QTCSOZJVLGOQBS-UHFFFAOYSA-N 3-[(3,4-dichlorophenyl)methoxy]-5-[(3-hydroxy-2-methylpropyl)carbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NCC(CO)C)SN=C1OCC1=CC=C(Cl)C(Cl)=C1 QTCSOZJVLGOQBS-UHFFFAOYSA-N 0.000 description 1
- SAVJBMJONYOYGS-UHFFFAOYSA-N 3-[(3,4-dichlorophenyl)methylsulfanyl]-5-(2-methylpropylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NCC(C)C)SN=C1SCC1=CC=C(Cl)C(Cl)=C1 SAVJBMJONYOYGS-UHFFFAOYSA-N 0.000 description 1
- AUTYFOFRJSVGGI-UHFFFAOYSA-N 3-[(3,5-difluorophenyl)methoxy]-5-(dimethylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N(C)C)SN=C1OCC1=CC(F)=CC(F)=C1 AUTYFOFRJSVGGI-UHFFFAOYSA-N 0.000 description 1
- LMKOYHXQBCTIQE-UHFFFAOYSA-N 3-[(3-bromophenyl)methoxy]-5-(dimethylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N(C)C)SN=C1OCC1=CC=CC(Br)=C1 LMKOYHXQBCTIQE-UHFFFAOYSA-N 0.000 description 1
- QFICIQKWQFJJMF-UHFFFAOYSA-N 3-[(3-chloro-2,6-difluoro-4-methylphenyl)methoxy]-5-[4-(dimethylamino)butylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NCCCCN(C)C)SN=C1OCC1=C(F)C=C(C)C(Cl)=C1F QFICIQKWQFJJMF-UHFFFAOYSA-N 0.000 description 1
- CRXPKSGWTBXDLE-UHFFFAOYSA-N 3-[(3-methoxyphenyl)methylsulfanyl]-5-(2-methylpropylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound COC1=CC=CC(CSC=2C(=C(NC(=O)NCC(C)C)SN=2)C(N)=O)=C1 CRXPKSGWTBXDLE-UHFFFAOYSA-N 0.000 description 1
- XLGVMMYUIFCCGQ-UHFFFAOYSA-N 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-[5-[4-(2-hydroxyethyl)piperazin-1-yl]pentylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound S1N=C(OCC=2C(=CC(Br)=CC=2F)F)C(C(=O)N)=C1NC(=O)NCCCCCN1CCN(CCO)CC1 XLGVMMYUIFCCGQ-UHFFFAOYSA-N 0.000 description 1
- DJUQLEATJQMMEA-UHFFFAOYSA-N 3-[(4-bromo-2-fluorophenyl)methoxy]-5-(2-hydroxybutylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NCC(O)CC)SN=C1OCC1=CC=C(Br)C=C1F DJUQLEATJQMMEA-UHFFFAOYSA-N 0.000 description 1
- RHWLDLVDPFTNJQ-UHFFFAOYSA-N 3-[(4-bromo-2-fluorophenyl)methoxy]-5-(2-methylpropylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NCC(C)C)SN=C1OCC1=CC=C(Br)C=C1F RHWLDLVDPFTNJQ-UHFFFAOYSA-N 0.000 description 1
- LUFVDQXNPIHRHA-UHFFFAOYSA-N 3-[(4-bromo-2-fluorophenyl)methoxy]-5-(3-hydroxypropylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NCCCO)SN=C1OCC1=CC=C(Br)C=C1F LUFVDQXNPIHRHA-UHFFFAOYSA-N 0.000 description 1
- LHEFWGPBMSKOEA-UHFFFAOYSA-N 3-[(4-bromo-2-fluorophenyl)methoxy]-5-(dimethylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N(C)C)SN=C1OCC1=CC=C(Br)C=C1F LHEFWGPBMSKOEA-UHFFFAOYSA-N 0.000 description 1
- UCYUNWZLSKLNQL-UHFFFAOYSA-N 3-[(4-bromo-2-fluorophenyl)methoxy]-5-(furan-2-ylmethylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound S1N=C(OCC=2C(=CC(Br)=CC=2)F)C(C(=O)N)=C1NC(=O)NCC1=CC=CO1 UCYUNWZLSKLNQL-UHFFFAOYSA-N 0.000 description 1
- BDORUPCHAUSPPS-UHFFFAOYSA-N 3-[(4-bromo-2-fluorophenyl)methoxy]-5-[(2-hydroxy-3,3-dimethylbutyl)carbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NCC(O)C(C)(C)C)SN=C1OCC1=CC=C(Br)C=C1F BDORUPCHAUSPPS-UHFFFAOYSA-N 0.000 description 1
- ZTCBZQQUSZMFJU-UHFFFAOYSA-N 3-[(4-bromo-2-fluorophenyl)methoxy]-5-[(2-methyl-3-piperidin-1-ylpropyl)carbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound C1CCCCN1CC(C)CNC(=O)NC(=C1C(N)=O)SN=C1OCC1=CC=C(Br)C=C1F ZTCBZQQUSZMFJU-UHFFFAOYSA-N 0.000 description 1
- URJMYHJUKOHKNZ-UHFFFAOYSA-N 3-[(4-bromo-2-fluorophenyl)methoxy]-5-[3-(2-methylpiperidin-1-yl)propylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound CC1CCCCN1CCCNC(=O)NC1=C(C(N)=O)C(OCC=2C(=CC(Br)=CC=2)F)=NS1 URJMYHJUKOHKNZ-UHFFFAOYSA-N 0.000 description 1
- NFUGDURMQNOAAJ-UHFFFAOYSA-N 3-[(4-bromo-2-fluorophenyl)methoxy]-5-[3-(dimethylamino)propylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NCCCN(C)C)SN=C1OCC1=CC=C(Br)C=C1F NFUGDURMQNOAAJ-UHFFFAOYSA-N 0.000 description 1
- YOAPARRQKCQDEQ-UHFFFAOYSA-N 3-[(4-bromo-2-fluorophenyl)methoxy]-5-[6-(dimethylamino)hexylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NCCCCCCN(C)C)SN=C1OCC1=CC=C(Br)C=C1F YOAPARRQKCQDEQ-UHFFFAOYSA-N 0.000 description 1
- YRXZENYHAZGPBF-UHFFFAOYSA-N 3-[(4-chloro-2,3,6-trifluorophenyl)methoxy]-5-(4-pyrrolidin-1-ylbutylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound S1N=C(OCC=2C(=C(F)C(Cl)=CC=2F)F)C(C(=O)N)=C1NC(=O)NCCCCN1CCCC1 YRXZENYHAZGPBF-UHFFFAOYSA-N 0.000 description 1
- NKGBEPBSPHYERX-UHFFFAOYSA-N 3-[(4-chloro-2,3,6-trifluorophenyl)methoxy]-5-[(3-hydroxy-5-pyrrolidin-1-ylpentyl)carbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound S1N=C(OCC=2C(=C(F)C(Cl)=CC=2F)F)C(C(=O)N)=C1NC(=O)NCCC(O)CCN1CCCC1 NKGBEPBSPHYERX-UHFFFAOYSA-N 0.000 description 1
- IAPRHFGAJVARMX-UHFFFAOYSA-N 3-[(4-chloro-2,5-difluorophenyl)methoxy]-5-(2-morpholin-4-ylethylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound S1N=C(OCC=2C(=CC(Cl)=C(F)C=2)F)C(C(=O)N)=C1NC(=O)NCCN1CCOCC1 IAPRHFGAJVARMX-UHFFFAOYSA-N 0.000 description 1
- CFOPLRVAENEPQU-UHFFFAOYSA-N 3-[(4-chloro-2,5-difluorophenyl)methoxy]-5-(4-piperidin-1-ylbutylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound S1N=C(OCC=2C(=CC(Cl)=C(F)C=2)F)C(C(=O)N)=C1NC(=O)NCCCCN1CCCCC1 CFOPLRVAENEPQU-UHFFFAOYSA-N 0.000 description 1
- DYXDBPVFORCONR-UHFFFAOYSA-N 3-[(4-chloro-2,5-difluorophenyl)methoxy]-5-(morpholin-2-ylmethylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound S1N=C(OCC=2C(=CC(Cl)=C(F)C=2)F)C(C(=O)N)=C1NC(=O)NCC1CNCCO1 DYXDBPVFORCONR-UHFFFAOYSA-N 0.000 description 1
- KWNIQQGILOMODK-UHFFFAOYSA-N 3-[(4-chloro-2,5-difluorophenyl)methoxy]-5-[4-(3,4-dihydroxypyrrolidin-1-yl)butylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound S1N=C(OCC=2C(=CC(Cl)=C(F)C=2)F)C(C(=O)N)=C1NC(=O)NCCCCN1CC(O)C(O)C1 KWNIQQGILOMODK-UHFFFAOYSA-N 0.000 description 1
- MOLVXMOSAIRSFJ-UHFFFAOYSA-N 3-[(4-chloro-2,5-difluorophenyl)methoxy]-5-[4-(5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)butylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound CN1CC2CC1CN2CCCCNC(=O)NC(=C1C(N)=O)SN=C1OCC1=CC(F)=C(Cl)C=C1F MOLVXMOSAIRSFJ-UHFFFAOYSA-N 0.000 description 1
- GCEYRFMTSGZNRR-UHFFFAOYSA-N 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-(4-piperidin-1-ylbutylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound S1N=C(OCC=2C(=CC(Cl)=CC=2F)F)C(C(=O)N)=C1NC(=O)NCCCCN1CCCCC1 GCEYRFMTSGZNRR-UHFFFAOYSA-N 0.000 description 1
- QKKMGJRYCFFKSN-UHFFFAOYSA-N 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-[(6-hydroxy-7-morpholin-4-ylheptyl)carbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound S1N=C(OCC=2C(=CC(Cl)=CC=2F)F)C(C(=O)N)=C1NC(=O)NCCCCCC(O)CN1CCOCC1 QKKMGJRYCFFKSN-UHFFFAOYSA-N 0.000 description 1
- MWVBCIVIIYFBBQ-UHFFFAOYSA-N 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-[(6-hydroxy-7-piperidin-1-ylheptyl)carbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound S1N=C(OCC=2C(=CC(Cl)=CC=2F)F)C(C(=O)N)=C1NC(=O)NCCCCCC(O)CN1CCCCC1 MWVBCIVIIYFBBQ-UHFFFAOYSA-N 0.000 description 1
- NYYQETQHPXRWLV-UHFFFAOYSA-N 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-[2-(1-methylpyrrolidin-2-yl)ethylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound CN1CCCC1CCNC(=O)NC1=C(C(N)=O)C(OCC=2C(=CC(Cl)=CC=2F)F)=NS1 NYYQETQHPXRWLV-UHFFFAOYSA-N 0.000 description 1
- PZZKUCCOCXREFT-UHFFFAOYSA-N 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-[4-(3-hydroxypiperidin-1-yl)butylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound S1N=C(OCC=2C(=CC(Cl)=CC=2F)F)C(C(=O)N)=C1NC(=O)NCCCCN1CCCC(O)C1 PZZKUCCOCXREFT-UHFFFAOYSA-N 0.000 description 1
- DGXJAGGCMLMDSU-UHFFFAOYSA-N 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-[4-[2-(hydroxymethyl)piperidin-1-yl]butylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound S1N=C(OCC=2C(=CC(Cl)=CC=2F)F)C(C(=O)N)=C1NC(=O)NCCCCN1CCCCC1CO DGXJAGGCMLMDSU-UHFFFAOYSA-N 0.000 description 1
- VVGYSCAXHFUTCI-UHFFFAOYSA-N 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-[4-[2-(methoxymethyl)pyrrolidin-1-yl]butylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound COCC1CCCN1CCCCNC(=O)NC1=C(C(N)=O)C(OCC=2C(=CC(Cl)=CC=2F)F)=NS1 VVGYSCAXHFUTCI-UHFFFAOYSA-N 0.000 description 1
- GYQMQSXDMPCZGJ-UHFFFAOYSA-N 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-[5-(propan-2-ylamino)pentylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NCCCCCNC(C)C)SN=C1OCC1=C(F)C=C(Cl)C=C1F GYQMQSXDMPCZGJ-UHFFFAOYSA-N 0.000 description 1
- RWCKNYQTVBRIFZ-UHFFFAOYSA-N 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-[[7-(dimethylamino)-6-hydroxyheptyl]carbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NCCCCCC(O)CN(C)C)SN=C1OCC1=C(F)C=C(Cl)C=C1F RWCKNYQTVBRIFZ-UHFFFAOYSA-N 0.000 description 1
- QUPOZDYCRNQHHJ-UHFFFAOYSA-N 3-[(4-chloro-2,6-difluorophenyl)methoxy]-5-[[methyl-[3-(4-methylpiperazin-1-yl)propyl]carbamoyl]amino]-1,2-thiazole-4-carboxamide Chemical compound S1N=C(OCC=2C(=CC(Cl)=CC=2F)F)C(C(N)=O)=C1NC(=O)N(C)CCCN1CCN(C)CC1 QUPOZDYCRNQHHJ-UHFFFAOYSA-N 0.000 description 1
- AHGHOTCEKOVFRH-UHFFFAOYSA-N 3-[(4-chloro-2-fluorophenyl)methoxy]-5-[2-(1h-imidazol-5-yl)ethylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound S1N=C(OCC=2C(=CC(Cl)=CC=2)F)C(C(=O)N)=C1NC(=O)NCCC1=CNC=N1 AHGHOTCEKOVFRH-UHFFFAOYSA-N 0.000 description 1
- YIXJNXQZIMPDDK-UHFFFAOYSA-N 3-[(4-chlorophenyl)methylsulfanyl]-5-(2-methylpropylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NCC(C)C)SN=C1SCC1=CC=C(Cl)C=C1 YIXJNXQZIMPDDK-UHFFFAOYSA-N 0.000 description 1
- JTGQAMIRDDCCOB-UHFFFAOYSA-N 3-[(4-chlorophenyl)methylsulfanyl]-5-(cyclopropylmethylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound N=1SC(NC(=O)NCC2CC2)=C(C(=O)N)C=1SCC1=CC=C(Cl)C=C1 JTGQAMIRDDCCOB-UHFFFAOYSA-N 0.000 description 1
- KEINKXYFHGEISK-UHFFFAOYSA-N 3-[(4-chlorophenyl)methylsulfanyl]-5-(furan-2-ylmethylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound N=1SC(NC(=O)NCC=2OC=CC=2)=C(C(=O)N)C=1SCC1=CC=C(Cl)C=C1 KEINKXYFHGEISK-UHFFFAOYSA-N 0.000 description 1
- OJNYWHSZTYNGPE-UHFFFAOYSA-N 3-[(4-chlorophenyl)methylsulfanyl]-5-(methylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NC)SN=C1SCC1=CC=C(Cl)C=C1 OJNYWHSZTYNGPE-UHFFFAOYSA-N 0.000 description 1
- VCTLNQDLLIMZDL-UHFFFAOYSA-N 3-[(4-chlorophenyl)methylsulfanyl]-5-[(3,4-difluorophenyl)methylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound N=1SC(NC(=O)NCC=2C=C(F)C(F)=CC=2)=C(C(=O)N)C=1SCC1=CC=C(Cl)C=C1 VCTLNQDLLIMZDL-UHFFFAOYSA-N 0.000 description 1
- SZYAWLZQZGAAKB-UHFFFAOYSA-N 3-[(4-chlorophenyl)methylsulfanyl]-5-[2-(1h-imidazol-5-yl)ethylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound N=1SC(NC(=O)NCCC=2N=CNC=2)=C(C(=O)N)C=1SCC1=CC=C(Cl)C=C1 SZYAWLZQZGAAKB-UHFFFAOYSA-N 0.000 description 1
- OUCIJFQKCMFIPH-UHFFFAOYSA-N 3-[(4-ethyl-2,3-difluorophenyl)methoxy]-5-(3-imidazol-1-ylpropylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound FC1=C(F)C(CC)=CC=C1COC1=NSC(NC(=O)NCCCN2C=NC=C2)=C1C(N)=O OUCIJFQKCMFIPH-UHFFFAOYSA-N 0.000 description 1
- HAROYSAOGFGKDV-UHFFFAOYSA-N 3-[(4-ethyl-2,3-difluorophenyl)methoxy]-5-(4-morpholin-4-ylbutylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound FC1=C(F)C(CC)=CC=C1COC1=NSC(NC(=O)NCCCCN2CCOCC2)=C1C(N)=O HAROYSAOGFGKDV-UHFFFAOYSA-N 0.000 description 1
- OYIHRERXHYWMAP-UHFFFAOYSA-N 3-[(4-ethyl-2,3-difluorophenyl)methoxy]-5-[(5-hydroxy-6-piperidin-1-ylhexyl)carbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound FC1=C(F)C(CC)=CC=C1COC1=NSC(NC(=O)NCCCCC(O)CN2CCCCC2)=C1C(N)=O OYIHRERXHYWMAP-UHFFFAOYSA-N 0.000 description 1
- WSAPJPXPXBJAKU-UHFFFAOYSA-N 3-[(4-ethyl-2,3-difluorophenyl)methoxy]-5-[3-(propan-2-ylamino)propylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound FC1=C(F)C(CC)=CC=C1COC1=NSC(NC(=O)NCCCNC(C)C)=C1C(N)=O WSAPJPXPXBJAKU-UHFFFAOYSA-N 0.000 description 1
- FFSUGKXRGIAMJD-UHFFFAOYSA-N 3-[(4-ethyl-2,5-difluorophenyl)methoxy]-5-(2-hydroxypropylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound C1=C(F)C(CC)=CC(F)=C1COC1=NSC(NC(=O)NCC(C)O)=C1C(N)=O FFSUGKXRGIAMJD-UHFFFAOYSA-N 0.000 description 1
- UVROXDZCFXWOMX-UHFFFAOYSA-N 3-[(4-ethyl-2,5-difluorophenyl)methoxy]-5-(2-methylpropylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound C1=C(F)C(CC)=CC(F)=C1COC1=NSC(NC(=O)NCC(C)C)=C1C(N)=O UVROXDZCFXWOMX-UHFFFAOYSA-N 0.000 description 1
- MHAMGJQMNIZNOL-UHFFFAOYSA-N 3-[(4-ethyl-2,5-difluorophenyl)methoxy]-5-(furan-2-ylmethylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound C1=C(F)C(CC)=CC(F)=C1COC1=NSC(NC(=O)NCC=2OC=CC=2)=C1C(N)=O MHAMGJQMNIZNOL-UHFFFAOYSA-N 0.000 description 1
- CAWXZHBORFTSNM-UHFFFAOYSA-N 3-[(4-ethyl-2,5-difluorophenyl)methoxy]-5-[(3-hydroxy-2-methylpropyl)carbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound C1=C(F)C(CC)=CC(F)=C1COC1=NSC(NC(=O)NCC(C)CO)=C1C(N)=O CAWXZHBORFTSNM-UHFFFAOYSA-N 0.000 description 1
- GOWJPEXLZUYJHQ-UHFFFAOYSA-N 3-[(4-ethylphenyl)methoxy]-5-[5-[4-(2-hydroxyethyl)piperazin-1-yl]pentylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound C1=CC(CC)=CC=C1COC1=NSC(NC(=O)NCCCCCN2CCN(CCO)CC2)=C1C(N)=O GOWJPEXLZUYJHQ-UHFFFAOYSA-N 0.000 description 1
- DJNZQZZLNHTNQA-UHFFFAOYSA-N 3-[(4-ethylphenyl)methoxy]-5-[6-[4-(2-hydroxyethyl)piperazin-1-yl]hexylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound C1=CC(CC)=CC=C1COC1=NSC(NC(=O)NCCCCCCN2CCN(CCO)CC2)=C1C(N)=O DJNZQZZLNHTNQA-UHFFFAOYSA-N 0.000 description 1
- HNUNBOFBTHXHTO-UHFFFAOYSA-N 3-[(4-fluorophenyl)methylsulfanyl]-5-(2-methylpropylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NCC(C)C)SN=C1SCC1=CC=C(F)C=C1 HNUNBOFBTHXHTO-UHFFFAOYSA-N 0.000 description 1
- QZKFUWHCGHLHBO-UHFFFAOYSA-N 3-[(4-methylphenyl)methoxy]-5-[2-(propan-2-ylamino)ethylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NCCNC(C)C)SN=C1OCC1=CC=C(C)C=C1 QZKFUWHCGHLHBO-UHFFFAOYSA-N 0.000 description 1
- QNDJIHMXABRFRA-UHFFFAOYSA-N 3-[(4-tert-butylphenyl)methoxy]-5-(dimethylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N(C)C)SN=C1OCC1=CC=C(C(C)(C)C)C=C1 QNDJIHMXABRFRA-UHFFFAOYSA-N 0.000 description 1
- ZRKQFCJMRPTAJY-UHFFFAOYSA-N 3-[(5-chloro-2-fluoro-4-methylphenyl)methoxy]-5-[4-[4-(3-hydroxypropyl)piperazin-1-yl]butylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound C1=C(Cl)C(C)=CC(F)=C1COC1=NSC(NC(=O)NCCCCN2CCN(CCCO)CC2)=C1C(N)=O ZRKQFCJMRPTAJY-UHFFFAOYSA-N 0.000 description 1
- ABGUXSSESXZTGY-UHFFFAOYSA-N 3-[(5-chlorothiophen-2-yl)methoxy]-5-(cyclopropylmethylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound N=1SC(NC(=O)NCC2CC2)=C(C(=O)N)C=1OCC1=CC=C(Cl)S1 ABGUXSSESXZTGY-UHFFFAOYSA-N 0.000 description 1
- VCBDGZDYTWDTKK-UHFFFAOYSA-N 3-[(5-chlorothiophen-2-yl)methoxy]-5-[(3,4-difluorophenyl)methylcarbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound S1N=C(OCC=2SC(Cl)=CC=2)C(C(=O)N)=C1NC(=O)NCC1=CC=C(F)C(F)=C1 VCBDGZDYTWDTKK-UHFFFAOYSA-N 0.000 description 1
- RDNDCJXUEZMDAV-UHFFFAOYSA-N 3-[(5-chlorothiophen-2-yl)methoxy]-5-[(3-hydroxy-2-methylpropyl)carbamoylamino]-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NCC(CO)C)SN=C1OCC1=CC=C(Cl)S1 RDNDCJXUEZMDAV-UHFFFAOYSA-N 0.000 description 1
- QHOYXMJKWIXSLE-UHFFFAOYSA-N 3-[(5-methylthiophen-2-yl)methylsulfanyl]-5-(2-morpholin-4-ylethylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound S1C(C)=CC=C1CSC1=NSC(NC(=O)NCCN2CCOCC2)=C1C(N)=O QHOYXMJKWIXSLE-UHFFFAOYSA-N 0.000 description 1
- ZXERMVHHPLEYOU-UHFFFAOYSA-N 3-benzylsulfanyl-5-(3-hydroxypropylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound S1C(NC(=O)NCCCO)=C(C(=O)N)C(SCC=2C=CC=CC=2)=N1 ZXERMVHHPLEYOU-UHFFFAOYSA-N 0.000 description 1
- XNERQTOLWZZJGE-UHFFFAOYSA-N 3-benzylsulfanyl-5-(methylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NC)SN=C1SCC1=CC=CC=C1 XNERQTOLWZZJGE-UHFFFAOYSA-N 0.000 description 1
- DABHQEZDOHPFNJ-UHFFFAOYSA-N 3-butoxy-5-(dimethylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound CCCCOC1=NSC(NC(=O)N(C)C)=C1C(N)=O DABHQEZDOHPFNJ-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- LFCGJZQEFSGOEL-UHFFFAOYSA-N 3-cyclohexylsulfanyl-5-(methylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NC)SN=C1SC1CCCCC1 LFCGJZQEFSGOEL-UHFFFAOYSA-N 0.000 description 1
- FUHBNPBOMULCIC-UHFFFAOYSA-N 3-cyclopentylsulfanyl-5-(dimethylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N(C)C)SN=C1SC1CCCC1 FUHBNPBOMULCIC-UHFFFAOYSA-N 0.000 description 1
- YNZHUXFDHCWZLL-UHFFFAOYSA-N 3-heptoxy-5-(3-hydroxypropylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound CCCCCCCOC1=NSC(NC(=O)NCCCO)=C1C(N)=O YNZHUXFDHCWZLL-UHFFFAOYSA-N 0.000 description 1
- PVZALKZESJGOOY-UHFFFAOYSA-N 3-heptoxy-5-(methylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound CCCCCCCOC1=NSC(NC(=O)NC)=C1C(N)=O PVZALKZESJGOOY-UHFFFAOYSA-N 0.000 description 1
- WEMHKLXCABMPSS-UHFFFAOYSA-N 3-hexylsulfanyl-5-(2-hydroxypropylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound CCCCCCSC1=NSC(NC(=O)NCC(C)O)=C1C(N)=O WEMHKLXCABMPSS-UHFFFAOYSA-N 0.000 description 1
- KOYSHZUYYAHEQZ-UHFFFAOYSA-N 3-hexylsulfanyl-5-(2-methoxyethylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound CCCCCCSC1=NSC(NC(=O)NCCOC)=C1C(N)=O KOYSHZUYYAHEQZ-UHFFFAOYSA-N 0.000 description 1
- CSKSWFGBRRUIOB-UHFFFAOYSA-N 3-hexylsulfanyl-5-(2-methylpropylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound CCCCCCSC1=NSC(NC(=O)NCC(C)C)=C1C(N)=O CSKSWFGBRRUIOB-UHFFFAOYSA-N 0.000 description 1
- WQUQGAJZYUGQAR-UHFFFAOYSA-N 3-hexylsulfanyl-5-(propylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound CCCCCCSC1=NSC(NC(=O)NCCC)=C1C(N)=O WQUQGAJZYUGQAR-UHFFFAOYSA-N 0.000 description 1
- OHFPRMJBABIHDR-UHFFFAOYSA-N 3-pentylsulfanyl-5-(3-pyrrolidin-1-ylpropylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound CCCCCSC1=NSC(NC(=O)NCCCN2CCCC2)=C1C(N)=O OHFPRMJBABIHDR-UHFFFAOYSA-N 0.000 description 1
- SRCWZYNLFBYPCG-UHFFFAOYSA-N 3-propoxy-5-(pyridin-3-ylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound CCCOC1=NSC(NC(=O)NC=2C=NC=CC=2)=C1C(N)=O SRCWZYNLFBYPCG-UHFFFAOYSA-N 0.000 description 1
- BBFXTASUUMYUHY-UHFFFAOYSA-N 3-propoxy-5-(pyrrolidine-1-carbonylamino)-1,2-thiazole-4-carboxamide Chemical compound CCCOC1=NSC(NC(=O)N2CCCC2)=C1C(N)=O BBFXTASUUMYUHY-UHFFFAOYSA-N 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- UUVVBQGKUOBTGZ-UHFFFAOYSA-N 3-sulfanylidene-1,2-thiazole-4-carbonitrile Chemical compound C(#N)C=1C(=NSC1)S UUVVBQGKUOBTGZ-UHFFFAOYSA-N 0.000 description 1
- 125000001963 4 membered heterocyclic group Chemical group 0.000 description 1
- NXKRSMDVDRFSBV-UHFFFAOYSA-N 4-(4-methylpiperazin-1-yl)butan-1-amine Chemical compound CN1CCN(CCCCN)CC1 NXKRSMDVDRFSBV-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- WZTAGISNUIXNAD-UHFFFAOYSA-N 4-amino-1-(tert-butylamino)butan-2-ol Chemical compound CC(C)(C)NCC(O)CCN WZTAGISNUIXNAD-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- PEPCYJSDHYMIFN-UHFFFAOYSA-N 4-chloro-2,5-difluorobenzoic acid Chemical compound OC(=O)C1=CC(F)=C(Cl)C=C1F PEPCYJSDHYMIFN-UHFFFAOYSA-N 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- YKSKIZPSIQNNOI-UHFFFAOYSA-N 5-(2,3,4,6,7,8,9,9a-octahydro-1h-pyrido[1,2-a]pyrazin-7-ylmethylcarbamoylamino)-3-[(4-chloro-2,5-difluorophenyl)methoxy]-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NCC2CN3CCNCC3CC2)SN=C1OCC1=CC(F)=C(Cl)C=C1F YKSKIZPSIQNNOI-UHFFFAOYSA-N 0.000 description 1
- TUMVHZSWCXACOE-UHFFFAOYSA-N 5-(2,3-dihydroxypropylcarbamoylamino)-3-[(4-ethyl-2,3-difluorophenyl)methoxy]-1,2-thiazole-4-carboxamide Chemical compound FC1=C(F)C(CC)=CC=C1COC1=NSC(NC(=O)NCC(O)CO)=C1C(N)=O TUMVHZSWCXACOE-UHFFFAOYSA-N 0.000 description 1
- XSQIOSXOMORCHB-UHFFFAOYSA-N 5-(2-cyanoethylcarbamoylamino)-3-pentylsulfanyl-1,2-thiazole-4-carboxamide Chemical compound CCCCCSC1=NSC(NC(=O)NCCC#N)=C1C(N)=O XSQIOSXOMORCHB-UHFFFAOYSA-N 0.000 description 1
- DKCLRPGKQQEKRE-UHFFFAOYSA-N 5-(2-methylpropylcarbamoylamino)-3-pentylsulfanyl-1,2-thiazole-4-carboxamide Chemical compound CCCCCSC1=NSC(NC(=O)NCC(C)C)=C1C(N)=O DKCLRPGKQQEKRE-UHFFFAOYSA-N 0.000 description 1
- ZLVRSRGLCRJQCU-UHFFFAOYSA-N 5-(3-methoxypropylcarbamoylamino)-3-pentylsulfanyl-1,2-thiazole-4-carboxamide Chemical compound CCCCCSC1=NSC(NC(=O)NCCCOC)=C1C(N)=O ZLVRSRGLCRJQCU-UHFFFAOYSA-N 0.000 description 1
- SLLNVQWGDVEWPT-UHFFFAOYSA-N 5-(benzylcarbamoylamino)-3-propoxy-1,2-thiazole-4-carboxamide Chemical compound CCCOC1=NSC(NC(=O)NCC=2C=CC=CC=2)=C1C(N)=O SLLNVQWGDVEWPT-UHFFFAOYSA-N 0.000 description 1
- ZUTUQKGUPPVOGH-UHFFFAOYSA-N 5-(butan-2-ylcarbamoylamino)-3-[(4-chlorophenyl)methylsulfanyl]-1,2-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=C(NC(=O)NC(C)CC)SN=C1SCC1=CC=C(Cl)C=C1 ZUTUQKGUPPVOGH-UHFFFAOYSA-N 0.000 description 1
- VEROLWGSLIQNKJ-UHFFFAOYSA-N 5-(butylcarbamoylamino)-3-heptoxy-1,2-thiazole-4-carboxamide Chemical compound CCCCCCCOC1=NSC(NC(=O)NCCCC)=C1C(N)=O VEROLWGSLIQNKJ-UHFFFAOYSA-N 0.000 description 1
- RTROYSDYWRFCCH-UHFFFAOYSA-N 5-(butylcarbamoylamino)-3-pentylsulfanyl-1,2-thiazole-4-carboxamide Chemical compound CCCCCSC1=NSC(NC(=O)NCCCC)=C1C(N)=O RTROYSDYWRFCCH-UHFFFAOYSA-N 0.000 description 1
- RJSLGXUKUQKLPZ-UHFFFAOYSA-N 5-(butylcarbamoylamino)-3-propylsulfanyl-1,2-thiazole-4-carboxamide Chemical compound CCCCNC(=O)NC=1SN=C(SCCC)C=1C(N)=O RJSLGXUKUQKLPZ-UHFFFAOYSA-N 0.000 description 1
- IQLITKYMHUBIRL-UHFFFAOYSA-N 5-(carbamoylamino)-3-propoxy-1,2-thiazole-4-carboxamide Chemical compound CCCOC1=NSC(NC(N)=O)=C1C(N)=O IQLITKYMHUBIRL-UHFFFAOYSA-N 0.000 description 1
- DOXCJGINROCVNU-UHFFFAOYSA-N 5-(cyclobutylcarbamoylamino)-3-[(2,6-difluoro-4-methylphenyl)methoxy]-1,2-thiazole-4-carboxamide Chemical compound FC1=CC(C)=CC(F)=C1COC1=NSC(NC(=O)NC2CCC2)=C1C(N)=O DOXCJGINROCVNU-UHFFFAOYSA-N 0.000 description 1
- SSZRNEQIAIXJHS-UHFFFAOYSA-N 5-(cyclopropylmethylcarbamoylamino)-3-[(3,4-dichlorophenyl)methylsulfanyl]-1,2-thiazole-4-carboxamide Chemical compound N=1SC(NC(=O)NCC2CC2)=C(C(=O)N)C=1SCC1=CC=C(Cl)C(Cl)=C1 SSZRNEQIAIXJHS-UHFFFAOYSA-N 0.000 description 1
- CMIHGGAPIRJKNS-UHFFFAOYSA-N 5-(dimethylcarbamoylamino)-3-(2-phenylethoxy)-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N(C)C)SN=C1OCCC1=CC=CC=C1 CMIHGGAPIRJKNS-UHFFFAOYSA-N 0.000 description 1
- VGFRQIJFSWKGQW-UHFFFAOYSA-N 5-(dimethylcarbamoylamino)-3-(2-phenylethylsulfanyl)-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N(C)C)SN=C1SCCC1=CC=CC=C1 VGFRQIJFSWKGQW-UHFFFAOYSA-N 0.000 description 1
- QCNRGJRBWLQEKR-UHFFFAOYSA-N 5-(dimethylcarbamoylamino)-3-(3-methylbut-2-enoxy)-1,2-thiazole-4-carboxamide Chemical compound CN(C)C(=O)NC=1SN=C(OCC=C(C)C)C=1C(N)=O QCNRGJRBWLQEKR-UHFFFAOYSA-N 0.000 description 1
- RXAGPTBBQLLRHN-UHFFFAOYSA-N 5-(dimethylcarbamoylamino)-3-(3-phenylmethoxypropoxy)-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N(C)C)SN=C1OCCCOCC1=CC=CC=C1 RXAGPTBBQLLRHN-UHFFFAOYSA-N 0.000 description 1
- FLNABYZUAASBIS-UHFFFAOYSA-N 5-(dimethylcarbamoylamino)-3-(4-methylpentoxy)-1,2-thiazole-4-carboxamide Chemical compound CC(C)CCCOC1=NSC(NC(=O)N(C)C)=C1C(N)=O FLNABYZUAASBIS-UHFFFAOYSA-N 0.000 description 1
- KBWUGXQFUVGONX-UHFFFAOYSA-N 5-(dimethylcarbamoylamino)-3-(naphthalen-1-ylmethoxy)-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N(C)C)SN=C1OCC1=CC=CC2=CC=CC=C12 KBWUGXQFUVGONX-UHFFFAOYSA-N 0.000 description 1
- JPIYPGDDMRNANF-UHFFFAOYSA-N 5-(dimethylcarbamoylamino)-3-(naphthalen-2-ylmethylsulfanyl)-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N(C)C)SN=C1SCC1=CC=C(C=CC=C2)C2=C1 JPIYPGDDMRNANF-UHFFFAOYSA-N 0.000 description 1
- OCEFNMNZMSXQDK-UHFFFAOYSA-N 5-(dimethylcarbamoylamino)-3-[(2,4,6-trimethylphenyl)methoxy]-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N(C)C)SN=C1OCC1=C(C)C=C(C)C=C1C OCEFNMNZMSXQDK-UHFFFAOYSA-N 0.000 description 1
- UDKWAOZNNMISGE-UHFFFAOYSA-N 5-(dimethylcarbamoylamino)-3-[(2,4-dimethylphenyl)methoxy]-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N(C)C)SN=C1OCC1=CC=C(C)C=C1C UDKWAOZNNMISGE-UHFFFAOYSA-N 0.000 description 1
- DASNPDURRNHEOV-UHFFFAOYSA-N 5-(dimethylcarbamoylamino)-3-[(2-fluorophenyl)methoxy]-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N(C)C)SN=C1OCC1=CC=CC=C1F DASNPDURRNHEOV-UHFFFAOYSA-N 0.000 description 1
- YTJZRVZLRTXKAA-UHFFFAOYSA-N 5-(dimethylcarbamoylamino)-3-[(3,4-dimethylphenyl)methoxy]-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N(C)C)SN=C1OCC1=CC=C(C)C(C)=C1 YTJZRVZLRTXKAA-UHFFFAOYSA-N 0.000 description 1
- LVLBAKVLAZNRQJ-UHFFFAOYSA-N 5-(dimethylcarbamoylamino)-3-[(3,4-dimethylphenyl)methylsulfanyl]-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N(C)C)SN=C1SCC1=CC=C(C)C(C)=C1 LVLBAKVLAZNRQJ-UHFFFAOYSA-N 0.000 description 1
- QQENWOWYTOYGFC-UHFFFAOYSA-N 5-(dimethylcarbamoylamino)-3-[(3-methoxyphenyl)methoxy]-1,2-thiazole-4-carboxamide Chemical compound COC1=CC=CC(COC=2C(=C(NC(=O)N(C)C)SN=2)C(N)=O)=C1 QQENWOWYTOYGFC-UHFFFAOYSA-N 0.000 description 1
- LMKZRYMJSORLFM-UHFFFAOYSA-N 5-(dimethylcarbamoylamino)-3-[(3-methylphenyl)methylsulfanyl]-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N(C)C)SN=C1SCC1=CC=CC(C)=C1 LMKZRYMJSORLFM-UHFFFAOYSA-N 0.000 description 1
- CUISXBGOCFPTQW-UHFFFAOYSA-N 5-(dimethylcarbamoylamino)-3-[(4-methoxyphenyl)methylsulfanyl]-1,2-thiazole-4-carboxylic acid Chemical compound C1=CC(OC)=CC=C1CSC1=NSC(NC(=O)N(C)C)=C1C(O)=O CUISXBGOCFPTQW-UHFFFAOYSA-N 0.000 description 1
- UJJOBMNRWTXQRP-UHFFFAOYSA-N 5-(dimethylcarbamoylamino)-3-[(4-methylphenyl)methoxy]-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N(C)C)SN=C1OCC1=CC=C(C)C=C1 UJJOBMNRWTXQRP-UHFFFAOYSA-N 0.000 description 1
- LNIOHAHWIYVRDJ-UHFFFAOYSA-N 5-(dimethylcarbamoylamino)-3-[(4-phenylphenyl)methoxy]-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N(C)C)SN=C1OCC1=CC=C(C=2C=CC=CC=2)C=C1 LNIOHAHWIYVRDJ-UHFFFAOYSA-N 0.000 description 1
- SSUAOMCMZLYSSM-UHFFFAOYSA-N 5-(dimethylcarbamoylamino)-3-[(4-propan-2-ylphenyl)methoxy]-1,2-thiazole-4-carboxamide Chemical compound C1=CC(C(C)C)=CC=C1COC1=NSC(NC(=O)N(C)C)=C1C(N)=O SSUAOMCMZLYSSM-UHFFFAOYSA-N 0.000 description 1
- BKLOPGCQBUHLNV-UHFFFAOYSA-N 5-(dimethylcarbamoylamino)-3-[[3-(trifluoromethyl)phenyl]methoxy]-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N(C)C)SN=C1OCC1=CC=CC(C(F)(F)F)=C1 BKLOPGCQBUHLNV-UHFFFAOYSA-N 0.000 description 1
- MRUXOJMBAPDFOH-UHFFFAOYSA-N 5-(dimethylcarbamoylamino)-3-[[4-(trifluoromethyl)phenyl]methoxy]-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N(C)C)SN=C1OCC1=CC=C(C(F)(F)F)C=C1 MRUXOJMBAPDFOH-UHFFFAOYSA-N 0.000 description 1
- VGFOJFVFHLTSSU-UHFFFAOYSA-N 5-(dimethylcarbamoylamino)-3-ethylsulfanyl-1,2-thiazole-4-carboxamide Chemical compound CCSC1=NSC(NC(=O)N(C)C)=C1C(N)=O VGFOJFVFHLTSSU-UHFFFAOYSA-N 0.000 description 1
- XPISKFCOJDBYBR-UHFFFAOYSA-N 5-(dimethylcarbamoylamino)-3-heptylsulfanyl-1,2-thiazole-4-carboxamide Chemical compound CCCCCCCSC1=NSC(NC(=O)N(C)C)=C1C(N)=O XPISKFCOJDBYBR-UHFFFAOYSA-N 0.000 description 1
- XIVWYRNAMGCNAE-UHFFFAOYSA-N 5-(dimethylcarbamoylamino)-3-methylsulfanyl-1,2-thiazole-4-carboxamide Chemical compound CSC1=NSC(NC(=O)N(C)C)=C1C(N)=O XIVWYRNAMGCNAE-UHFFFAOYSA-N 0.000 description 1
- HPOXCSUOTJYSBQ-UHFFFAOYSA-N 5-(dimethylcarbamoylamino)-3-oxo-1,2-thiazole-4-carboxamide Chemical compound CN(C)C(=O)NC=1SN=C(O)C=1C(N)=O HPOXCSUOTJYSBQ-UHFFFAOYSA-N 0.000 description 1
- KZROUNPFCFSRRD-UHFFFAOYSA-N 5-(dimethylcarbamoylamino)-3-pent-2-enoxy-1,2-thiazole-4-carboxamide Chemical compound CCC=CCOC1=NSC(NC(=O)N(C)C)=C1C(N)=O KZROUNPFCFSRRD-UHFFFAOYSA-N 0.000 description 1
- DTFXRKHFNMKFKB-UHFFFAOYSA-N 5-(dimethylcarbamoylamino)-3-pentylsulfanyl-1,2-thiazole-4-carboxamide Chemical compound CCCCCSC1=NSC(NC(=O)N(C)C)=C1C(N)=O DTFXRKHFNMKFKB-UHFFFAOYSA-N 0.000 description 1
- NSNFYNJDRNGTSE-UHFFFAOYSA-N 5-(dimethylcarbamoylamino)-3-propan-2-ylsulfanyl-1,2-thiazole-4-carboxamide Chemical compound CC(C)SC1=NSC(NC(=O)N(C)C)=C1C(N)=O NSNFYNJDRNGTSE-UHFFFAOYSA-N 0.000 description 1
- XEJOARPSCGWIII-UHFFFAOYSA-N 5-(dimethylcarbamoylamino)-3-propoxy-1,2-thiazole-4-carboxamide Chemical compound CCCOC1=NSC(NC(=O)N(C)C)=C1C(N)=O XEJOARPSCGWIII-UHFFFAOYSA-N 0.000 description 1
- KTXCVYMMHAFUTM-UHFFFAOYSA-N 5-(dimethylcarbamoylamino)-3-propylsulfanyl-1,2-thiazole-4-carboxamide Chemical compound CCCSC1=NSC(NC(=O)N(C)C)=C1C(N)=O KTXCVYMMHAFUTM-UHFFFAOYSA-N 0.000 description 1
- UXKZNEUXFAFOQL-UHFFFAOYSA-N 5-(ethylcarbamoylamino)-3-ethylsulfanyl-1,2-thiazole-4-carboxamide Chemical compound CCNC(=O)NC=1SN=C(SCC)C=1C(N)=O UXKZNEUXFAFOQL-UHFFFAOYSA-N 0.000 description 1
- GVLICQXIHBVMPF-UHFFFAOYSA-N 5-(ethylcarbamoylamino)-3-propoxy-1,2-thiazole-4-carboxamide Chemical compound CCCOC1=NSC(NC(=O)NCC)=C1C(N)=O GVLICQXIHBVMPF-UHFFFAOYSA-N 0.000 description 1
- SGZMYFZQNLIDPN-UHFFFAOYSA-N 5-(furan-2-ylmethylcarbamoylamino)-3-hexylsulfanyl-1,2-thiazole-4-carboxamide Chemical compound CCCCCCSC1=NSC(NC(=O)NCC=2OC=CC=2)=C1C(N)=O SGZMYFZQNLIDPN-UHFFFAOYSA-N 0.000 description 1
- FPEYLEMTKLFAQN-UHFFFAOYSA-N 5-(furan-2-ylmethylcarbamoylamino)-3-pentylsulfanyl-1,2-thiazole-4-carboxamide Chemical compound CCCCCSC1=NSC(NC(=O)NCC=2OC=CC=2)=C1C(N)=O FPEYLEMTKLFAQN-UHFFFAOYSA-N 0.000 description 1
- WJMRRSQFRXEXHM-UHFFFAOYSA-N 5-(methylcarbamoylamino)-3-methylsulfanyl-1,2-thiazole-4-carboxamide Chemical compound CNC(=O)NC=1SN=C(SC)C=1C(N)=O WJMRRSQFRXEXHM-UHFFFAOYSA-N 0.000 description 1
- ZWFHLTBZDHQFMT-UHFFFAOYSA-N 5-(methylcarbamoylamino)-3-pentylsulfanyl-1,2-thiazole-4-carboxamide Chemical compound CCCCCSC1=NSC(NC(=O)NC)=C1C(N)=O ZWFHLTBZDHQFMT-UHFFFAOYSA-N 0.000 description 1
- SQMGJDFBRGLMIM-UHFFFAOYSA-N 5-(methylcarbamoylamino)-3-phenylsulfanyl-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NC)SN=C1SC1=CC=CC=C1 SQMGJDFBRGLMIM-UHFFFAOYSA-N 0.000 description 1
- BWBOZLVPMOSDEO-UHFFFAOYSA-N 5-(methylcarbamoylamino)-3-propan-2-ylsulfanyl-1,2-thiazole-4-carboxamide Chemical compound CNC(=O)NC=1SN=C(SC(C)C)C=1C(N)=O BWBOZLVPMOSDEO-UHFFFAOYSA-N 0.000 description 1
- OXBJJTHWZCVWHV-UHFFFAOYSA-N 5-(methylcarbamoylamino)-3-propoxy-1,2-thiazole-4-carboxamide Chemical compound CCCOC1=NSC(NC(=O)NC)=C1C(N)=O OXBJJTHWZCVWHV-UHFFFAOYSA-N 0.000 description 1
- DSTVHGXXGCKGOQ-UHFFFAOYSA-N 5-(oxolan-2-ylmethylcarbamoylamino)-3-pentylsulfanyl-1,2-thiazole-4-carboxamide Chemical compound CCCCCSC1=NSC(NC(=O)NCC2OCCC2)=C1C(N)=O DSTVHGXXGCKGOQ-UHFFFAOYSA-N 0.000 description 1
- CEQLMANTHMBGLZ-UHFFFAOYSA-N 5-(pentylcarbamoylamino)-3-propoxy-1,2-thiazole-4-carboxamide Chemical compound CCCCCNC(=O)NC=1SN=C(OCCC)C=1C(N)=O CEQLMANTHMBGLZ-UHFFFAOYSA-N 0.000 description 1
- CNWJEZSXDOHFFS-UHFFFAOYSA-N 5-(piperidine-1-carbonylamino)-3-propoxy-1,2-thiazole-4-carboxamide Chemical compound CCCOC1=NSC(NC(=O)N2CCCCC2)=C1C(N)=O CNWJEZSXDOHFFS-UHFFFAOYSA-N 0.000 description 1
- HCLXUSBKZOSXPV-UHFFFAOYSA-N 5-[(3,4-difluorophenyl)methylcarbamoylamino]-3-[(4-methoxyphenyl)methylsulfanyl]-1,2-thiazole-4-carboxamide Chemical compound C1=CC(OC)=CC=C1CSC1=NSC(NC(=O)NCC=2C=C(F)C(F)=CC=2)=C1C(N)=O HCLXUSBKZOSXPV-UHFFFAOYSA-N 0.000 description 1
- WBOHUOGPDOPETQ-UHFFFAOYSA-N 5-[(3,4-difluorophenyl)methylcarbamoylamino]-3-[(5-methylthiophen-2-yl)methylsulfanyl]-1,2-thiazole-4-carboxamide Chemical compound S1C(C)=CC=C1CSC1=NSC(NC(=O)NCC=2C=C(F)C(F)=CC=2)=C1C(N)=O WBOHUOGPDOPETQ-UHFFFAOYSA-N 0.000 description 1
- FKGPQURXUSFAMJ-UHFFFAOYSA-N 5-[(3-chloro-4-fluorophenyl)methylcarbamoylamino]-3-[(4-methylphenyl)methylsulfanyl]-1,2-thiazole-4-carboxamide Chemical compound C1=CC(C)=CC=C1CSC1=NSC(NC(=O)NCC=2C=C(Cl)C(F)=CC=2)=C1C(N)=O FKGPQURXUSFAMJ-UHFFFAOYSA-N 0.000 description 1
- RBHHELBRBWBBTD-UHFFFAOYSA-N 5-[(4-hydroxy-5-piperidin-1-ylpentyl)carbamoylamino]-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]-1,2-thiazole-4-carboxamide Chemical compound FC1=C(F)C(C)=CC(F)=C1COC1=NSC(NC(=O)NCCCC(O)CN2CCCCC2)=C1C(N)=O RBHHELBRBWBBTD-UHFFFAOYSA-N 0.000 description 1
- UXQKAZFYWCHUSQ-UHFFFAOYSA-N 5-[(5-hydroxy-6-piperidin-1-ylhexyl)carbamoylamino]-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]-1,2-thiazole-4-carboxamide Chemical compound FC1=C(F)C(C)=CC(F)=C1COC1=NSC(NC(=O)NCCCCC(O)CN2CCCCC2)=C1C(N)=O UXQKAZFYWCHUSQ-UHFFFAOYSA-N 0.000 description 1
- UVQHJHCVTHOLOA-UHFFFAOYSA-N 5-[(5-hydroxy-7-piperidin-1-ylheptyl)carbamoylamino]-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]-1,2-thiazole-4-carboxamide Chemical compound FC1=C(F)C(C)=CC(F)=C1COC1=NSC(NC(=O)NCCCCC(O)CCN2CCCCC2)=C1C(N)=O UVQHJHCVTHOLOA-UHFFFAOYSA-N 0.000 description 1
- FZBQENYVKVLUGK-UHFFFAOYSA-N 5-[(5-methylfuran-2-yl)methylcarbamoylamino]-3-pentylsulfanyl-1,2-thiazole-4-carboxamide Chemical compound CCCCCSC1=NSC(NC(=O)NCC=2OC(C)=CC=2)=C1C(N)=O FZBQENYVKVLUGK-UHFFFAOYSA-N 0.000 description 1
- ZNDDIJVISGEOJC-UHFFFAOYSA-N 5-[2-(1h-imidazol-5-yl)ethylcarbamoylamino]-3-pentylsulfanyl-1,2-thiazole-4-carboxamide Chemical compound CCCCCSC1=NSC(NC(=O)NCCC=2N=CNC=2)=C1C(N)=O ZNDDIJVISGEOJC-UHFFFAOYSA-N 0.000 description 1
- VSQWCOSODUHMDM-UHFFFAOYSA-N 5-[2-(dimethylamino)ethylcarbamoylamino]-3-hexylsulfanyl-1,2-thiazole-4-carboxamide Chemical compound CCCCCCSC1=NSC(NC(=O)NCCN(C)C)=C1C(N)=O VSQWCOSODUHMDM-UHFFFAOYSA-N 0.000 description 1
- GKOMTUPLZUADPM-UHFFFAOYSA-N 5-[2-(dimethylamino)ethylcarbamoylamino]-3-pentylsulfanyl-1,2-thiazole-4-carboxamide Chemical compound CCCCCSC1=NSC(NC(=O)NCCN(C)C)=C1C(N)=O GKOMTUPLZUADPM-UHFFFAOYSA-N 0.000 description 1
- DCOCWWDLSMGDFV-UHFFFAOYSA-N 5-[3-(4-methylpiperazin-1-yl)propylcarbamoylamino]-3-[(2,3,6-trifluorophenyl)methoxy]-1,2-thiazole-4-carboxamide Chemical compound C1CN(C)CCN1CCCNC(=O)NC1=C(C(N)=O)C(OCC=2C(=C(F)C=CC=2F)F)=NS1 DCOCWWDLSMGDFV-UHFFFAOYSA-N 0.000 description 1
- WJHDEWSLSBKKGI-UHFFFAOYSA-N 5-[3-(cyclohexylamino)propylcarbamoylamino]-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]-1,2-thiazole-4-carboxamide Chemical compound FC1=C(F)C(C)=CC(F)=C1COC1=NSC(NC(=O)NCCCNC2CCCCC2)=C1C(N)=O WJHDEWSLSBKKGI-UHFFFAOYSA-N 0.000 description 1
- WXMYZVYEMXHCFL-UHFFFAOYSA-N 5-[3-(dimethylamino)propylcarbamoylamino]-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NCCCN(C)C)SN=C1OCC1=C(F)C=C(C)C(F)=C1F WXMYZVYEMXHCFL-UHFFFAOYSA-N 0.000 description 1
- VCGMCMMWRXRFCH-UHFFFAOYSA-N 5-[3-(dimethylamino)propylcarbamoylamino]-3-hexylsulfanyl-1,2-thiazole-4-carboxamide Chemical compound CCCCCCSC1=NSC(NC(=O)NCCCN(C)C)=C1C(N)=O VCGMCMMWRXRFCH-UHFFFAOYSA-N 0.000 description 1
- UFLMPWLAMMMPBH-UHFFFAOYSA-N 5-[3-(propan-2-ylamino)propylcarbamoylamino]-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NCCCNC(C)C)SN=C1OCC1=C(F)C=C(C)C(F)=C1F UFLMPWLAMMMPBH-UHFFFAOYSA-N 0.000 description 1
- NKQCTARIAOELEB-UHFFFAOYSA-N 5-[3-(tert-butylamino)propylcarbamoylamino]-3-[(2-fluoro-4,6-dimethylphenyl)methoxy]-1,2-thiazole-4-carboxamide Chemical compound FC1=CC(C)=CC(C)=C1COC1=NSC(NC(=O)NCCCNC(C)(C)C)=C1C(N)=O NKQCTARIAOELEB-UHFFFAOYSA-N 0.000 description 1
- RIBLQBOAPMXMPD-UHFFFAOYSA-N 5-[4-(3,4-dihydroxypyrrolidin-1-yl)butylcarbamoylamino]-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]-1,2-thiazole-4-carboxamide Chemical compound FC1=C(F)C(C)=CC(F)=C1COC1=NSC(NC(=O)NCCCCN2CC(O)C(O)C2)=C1C(N)=O RIBLQBOAPMXMPD-UHFFFAOYSA-N 0.000 description 1
- ROVDSHLCIHLXON-UHFFFAOYSA-N 5-[4-[bis(2-hydroxyethyl)amino]butylcarbamoylamino]-3-[(2,5-difluoro-4-methylphenyl)methoxy]-1,2-thiazole-4-carboxamide Chemical compound C1=C(F)C(C)=CC(F)=C1COC1=NSC(NC(=O)NCCCCN(CCO)CCO)=C1C(N)=O ROVDSHLCIHLXON-UHFFFAOYSA-N 0.000 description 1
- YIDLRYFBKWDNJD-UHFFFAOYSA-N 5-[4-[ethyl(2-hydroxyethyl)amino]butylcarbamoylamino]-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NCCCCN(CCO)CC)SN=C1OCC1=C(F)C=C(C)C(F)=C1F YIDLRYFBKWDNJD-UHFFFAOYSA-N 0.000 description 1
- VGIXYRYGUWVQAL-UHFFFAOYSA-N 5-[6-(dimethylamino)hexylcarbamoylamino]-3-[(2,3,6-trifluorophenyl)methoxy]-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)NCCCCCCN(C)C)SN=C1OCC1=C(F)C=CC(F)=C1F VGIXYRYGUWVQAL-UHFFFAOYSA-N 0.000 description 1
- FPDMXKWHLRZQJY-UHFFFAOYSA-N 5-[6-(dimethylamino)hexylcarbamoylamino]-3-heptoxy-1,2-thiazole-4-carboxamide Chemical compound CCCCCCCOC1=NSC(NC(=O)NCCCCCCN(C)C)=C1C(N)=O FPDMXKWHLRZQJY-UHFFFAOYSA-N 0.000 description 1
- RVEJKOFDHFCLKB-UHFFFAOYSA-N 5-[[3-aminopropyl(methyl)carbamoyl]amino]-3-[(2,3,6-trifluoro-4-methylphenyl)methoxy]-1,2-thiazole-4-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N(CCCN)C)SN=C1OCC1=C(F)C=C(C)C(F)=C1F RVEJKOFDHFCLKB-UHFFFAOYSA-N 0.000 description 1
- WRRFEBRKTUXSKT-UHFFFAOYSA-N 5-[[4-(tert-butylamino)-3-hydroxybutyl]carbamoylamino]-3-[(2-fluoro-4-methylphenyl)methoxy]-1,2-thiazole-4-carboxamide Chemical compound FC1=CC(C)=CC=C1COC1=NSC(NC(=O)NCCC(O)CNC(C)(C)C)=C1C(N)=O WRRFEBRKTUXSKT-UHFFFAOYSA-N 0.000 description 1
- HQJOBKHLTKHMRB-UHFFFAOYSA-N 5-acetamido-3-pentylsulfanyl-1,2-thiazole-4-carboxamide Chemical compound CCCCCSC1=NSC(NC(C)=O)=C1C(N)=O HQJOBKHLTKHMRB-UHFFFAOYSA-N 0.000 description 1
- IMBBVRNFDUZNKO-UHFFFAOYSA-N 5-amino-3-pentylsulfanyl-1,2-thiazole-4-carboxamide Chemical compound CCCCCSC1=NSC(N)=C1C(N)=O IMBBVRNFDUZNKO-UHFFFAOYSA-N 0.000 description 1
- YXYKTYXTUPDSTF-UHFFFAOYSA-N 5-amino-3-propoxy-1,2-thiazole-4-carboxamide Chemical compound CCCOC1=NSC(N)=C1C(N)=O YXYKTYXTUPDSTF-UHFFFAOYSA-N 0.000 description 1
- GPYAREOBBQESCD-UHFFFAOYSA-N 5-benzamido-3-pentylsulfanyl-1,2-thiazole-4-carboxamide Chemical compound CCCCCSC1=NSC(NC(=O)C=2C=CC=CC=2)=C1C(N)=O GPYAREOBBQESCD-UHFFFAOYSA-N 0.000 description 1
- YVFPFZOYFSLNJI-UHFFFAOYSA-N 7-[[[4-carbamoyl-3-[(4-chloro-2,5-difluorophenyl)methoxy]-1,2-thiazol-5-yl]carbamoylamino]methyl]-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazine-2-carboxylic acid Chemical compound NC(=O)C1=C(NC(=O)NCC2CN3CCN(CC3CC2)C(O)=O)SN=C1OCC1=CC(F)=C(Cl)C=C1F YVFPFZOYFSLNJI-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- KLDOBLWQCLHCPU-UHFFFAOYSA-N CCCCCSC1=NSC(NC(=O)N2CCC(O)CC2)=C1C(N)=O Chemical compound CCCCCSC1=NSC(NC(=O)N2CCC(O)CC2)=C1C(N)=O KLDOBLWQCLHCPU-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- CCPHAMSKHBDMDS-UHFFFAOYSA-N Chetoseminudin B Natural products C=1NC2=CC=CC=C2C=1CC1(SC)NC(=O)C(CO)(SC)N(C)C1=O CCPHAMSKHBDMDS-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- YIIMEMSDCNDGTB-UHFFFAOYSA-N Dimethylcarbamoyl chloride Chemical compound CN(C)C(Cl)=O YIIMEMSDCNDGTB-UHFFFAOYSA-N 0.000 description 1
- 101100117236 Drosophila melanogaster speck gene Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 244000299507 Gossypium hirsutum Species 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- UCUNFLYVYCGDHP-BYPYZUCNSA-N L-methionine sulfone Chemical compound CS(=O)(=O)CC[C@H](N)C(O)=O UCUNFLYVYCGDHP-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical class CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 1
- OVCCKBRTPHYBDB-UHFFFAOYSA-N N-(4-carbamoyl-3-pentylsulfanyl-1,2-thiazol-5-yl)morpholine-4-carboxamide Chemical compound CCCCCSC1=NSC(NC(=O)N2CCOCC2)=C1C(N)=O OVCCKBRTPHYBDB-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 101150073096 NRAS gene Proteins 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 241000292569 Pegusa lascaris Species 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000193803 Therea Species 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 201000003761 Vaginal carcinoma Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- CEBVKFVONMPTSV-UHFFFAOYSA-N acetic acid;dichloromethane;propan-2-one Chemical compound ClCCl.CC(C)=O.CC(O)=O CEBVKFVONMPTSV-UHFFFAOYSA-N 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 150000001347 alkyl bromides Chemical class 0.000 description 1
- 150000001348 alkyl chlorides Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 150000001356 alkyl thiols Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 125000005604 azodicarboxylate group Chemical group 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- YMJZVTRXKMWFCW-UHFFFAOYSA-N benzyl 2-cyanoethanimidate Chemical compound N#CCC(=N)OCC1=CC=CC=C1 YMJZVTRXKMWFCW-UHFFFAOYSA-N 0.000 description 1
- 150000003938 benzyl alcohols Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940045348 brown mixture Drugs 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- MXOSTENCGSDMRE-UHFFFAOYSA-N butyl-chloro-dimethylsilane Chemical compound CCCC[Si](C)(C)Cl MXOSTENCGSDMRE-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229910052801 chlorine Chemical group 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 101150087654 chrnd gene Proteins 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000000448 cultured tumor cell Anatomy 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- DGJMPUGMZIKDRO-UHFFFAOYSA-N cyanoacetamide Chemical compound NC(=O)CC#N DGJMPUGMZIKDRO-UHFFFAOYSA-N 0.000 description 1
- PYRZPBDTPRQYKG-UHFFFAOYSA-N cyclopentene-1-carboxylic acid Chemical compound OC(=O)C1=CCCC1 PYRZPBDTPRQYKG-UHFFFAOYSA-N 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- 125000006287 difluorobenzyl group Chemical group 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- UBHZUDXTHNMNLD-UHFFFAOYSA-N dimethylsilane Chemical compound C[SiH2]C UBHZUDXTHNMNLD-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
- CJERHVUGAROYES-UHFFFAOYSA-N ethyl n-(3-butoxy-4-carbamoyl-1,2-thiazol-5-yl)carbamate Chemical compound CCCCOC1=NSC(NC(=O)OCC)=C1C(N)=O CJERHVUGAROYES-UHFFFAOYSA-N 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 201000001343 fallopian tube carcinoma Diseases 0.000 description 1
- 208000028149 female reproductive system neoplasm Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Chemical group 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 102000055590 human KDR Human genes 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical group [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 150000002730 mercury Chemical class 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- JZENIGYSJWLQHS-UHFFFAOYSA-N methyl 4-[[4-carbamoyl-5-(2-methylpropylcarbamoylamino)-1,2-thiazol-3-yl]sulfanylmethyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CSC1=NSC(NC(=O)NCC(C)C)=C1C(N)=O JZENIGYSJWLQHS-UHFFFAOYSA-N 0.000 description 1
- AXMSPUGBZTWHDN-UHFFFAOYSA-N methyl 4-[[5-(butylcarbamoylamino)-4-carbamoyl-1,2-thiazol-3-yl]sulfanylmethyl]benzoate Chemical compound NC(=O)C1=C(NC(=O)NCCCC)SN=C1SCC1=CC=C(C(=O)OC)C=C1 AXMSPUGBZTWHDN-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- ZUXUNWLVIWKEHB-UHFFFAOYSA-N n',n'-dimethylhexane-1,6-diamine Chemical compound CN(C)CCCCCCN ZUXUNWLVIWKEHB-UHFFFAOYSA-N 0.000 description 1
- KFDIDIIKNMZLRZ-UHFFFAOYSA-N n'-propan-2-ylpropane-1,3-diamine Chemical compound CC(C)NCCCN KFDIDIIKNMZLRZ-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- QGPLGKCBLOZZSX-UHFFFAOYSA-N phenyl N-(3-amino-2-cyano-1-sulfanyl-3-sulfanylideneprop-1-enyl)carbamate Chemical compound C(#N)C(C(S)=N)=C(NC(=O)OC1=CC=CC=C1)S QGPLGKCBLOZZSX-UHFFFAOYSA-N 0.000 description 1
- QZMAIHNDXWNOND-UHFFFAOYSA-N phenyl n-(4-carbamoyl-3-oxo-1,2-thiazol-5-yl)carbamate Chemical compound OC1=NSC(NC(=O)OC=2C=CC=CC=2)=C1C(=O)N QZMAIHNDXWNOND-UHFFFAOYSA-N 0.000 description 1
- VHETYPIPPCUQEM-UHFFFAOYSA-N phenyl n-(4-carbamoyl-3-pentylsulfanyl-1,2-thiazol-5-yl)carbamate Chemical compound CCCCCSC1=NSC(NC(=O)OC=2C=CC=CC=2)=C1C(N)=O VHETYPIPPCUQEM-UHFFFAOYSA-N 0.000 description 1
- LMBGZNPXUVCPKZ-UHFFFAOYSA-N phenyl n-(4-cyano-3-phenylmethoxy-1,2-thiazol-5-yl)carbamate Chemical compound C=1C=CC=CC=1OC(=O)NC(=C1C#N)SN=C1OCC1=CC=CC=C1 LMBGZNPXUVCPKZ-UHFFFAOYSA-N 0.000 description 1
- DGUIBCQXYYINSX-UHFFFAOYSA-N phenyl n-[4-cyano-3-[(4-methoxyphenyl)methylsulfanyl]-1,2-thiazol-5-yl]carbamate Chemical compound C1=CC(OC)=CC=C1CSC1=NSC(NC(=O)OC=2C=CC=CC=2)=C1C#N DGUIBCQXYYINSX-UHFFFAOYSA-N 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 201000008171 proliferative glomerulonephritis Diseases 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003653 radioligand binding assay Methods 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- FUOXZDSJWWJDQW-UHFFFAOYSA-N tert-butyl-[(2,3-difluoro-4-methylphenyl)methoxy]-dimethylsilane Chemical compound CC1=CC=C(CO[Si](C)(C)C(C)(C)C)C(F)=C1F FUOXZDSJWWJDQW-UHFFFAOYSA-N 0.000 description 1
- PRCCOHWJPTXQPT-UHFFFAOYSA-N tert-butyl-[(2,3-difluorophenyl)methoxy]-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCC1=CC=CC(F)=C1F PRCCOHWJPTXQPT-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 208000013013 vulvar carcinoma Diseases 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
- C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/58—Derivatives of thiocarboxylic acids, the doubly-bound oxygen atoms being replaced by nitrogen atoms, e.g. imino-thio ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
- C07C33/40—Halogenated unsaturated alcohols
- C07C33/46—Halogenated unsaturated alcohols containing only six-membered aromatic rings as cyclic parts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8796398P | 1998-06-04 | 1998-06-04 | |
| US60/087,963 | 1998-06-04 | ||
| CA002333703A CA2333703C (en) | 1998-06-04 | 1999-05-03 | Isothiazole derivatives useful as anticancer agents |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002333703A Division CA2333703C (en) | 1998-06-04 | 1999-05-03 | Isothiazole derivatives useful as anticancer agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2475113A1 CA2475113A1 (en) | 1999-12-09 |
| CA2475113C true CA2475113C (en) | 2008-03-18 |
Family
ID=22208298
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002475113A Expired - Lifetime CA2475113C (en) | 1998-06-04 | 1999-05-03 | Isothiazole derivatives useful as anticancer agents |
| CA002333703A Expired - Lifetime CA2333703C (en) | 1998-06-04 | 1999-05-03 | Isothiazole derivatives useful as anticancer agents |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002333703A Expired - Lifetime CA2333703C (en) | 1998-06-04 | 1999-05-03 | Isothiazole derivatives useful as anticancer agents |
Country Status (45)
Families Citing this family (225)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849769A (en) * | 1994-08-24 | 1998-12-15 | Medivir Ab | N-arylalkyl-N-heteroarylurea and guandine compounds and methods of treating HIV infection |
| US6294532B1 (en) | 1997-08-22 | 2001-09-25 | Zeneca Limited | Oxindolylquinazoline derivatives as angiogenesis inhibitors |
| UA60365C2 (uk) * | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| ES2384160T3 (es) | 1999-01-13 | 2012-07-02 | Bayer Healthcare Llc | Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38 |
| RU2319693C9 (ru) | 1999-01-13 | 2008-08-20 | Байер Копэрейшн | Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты) |
| HUP0202708A3 (en) | 1999-04-15 | 2004-12-28 | Bristol Myers Squibb Co | Cyclic protein tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use |
| US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| HN2000000051A (es) * | 1999-05-19 | 2001-02-02 | Pfizer Prod Inc | Derivados heterociclicos utiles como agentes anticancerosos |
| ATE362940T1 (de) | 2000-03-16 | 2007-06-15 | Genesoft Inc | Geladene verbindungen mit einer nukleinsäure- bindenden einheit sowie deren verwendungen |
| US7078536B2 (en) | 2001-03-14 | 2006-07-18 | Genesoft Pharmaceuticals, Inc. | Charged compounds comprising a nucleic acid binding moiety and uses therefor |
| CA2411928A1 (en) | 2000-08-09 | 2002-02-14 | Agouron Pharmaceuticals, Inc. | Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclindependent kinases |
| WO2002014305A2 (en) | 2000-08-17 | 2002-02-21 | Lumera Corporation | Design and synthesis of advanced nlo materials for electro-optic applications |
| MXPA03001452A (es) | 2000-08-18 | 2004-05-04 | Agouron Pharma | Hidroximino-fluorenos heterociclicos y su uso para la inhibicion de las proteinas cinasas. |
| WO2002032872A1 (fr) | 2000-10-20 | 2002-04-25 | Eisai Co., Ltd. | Composes a noyau aromatique azote |
| MXPA03004714A (es) * | 2000-11-28 | 2003-08-19 | Pfizer Prod Inc | Sales de una isotiazol-4-carboxamida y su uso como agentes de antihiperproliferacion. |
| KR100847169B1 (ko) | 2000-12-21 | 2008-07-17 | 글락소 그룹 리미티드 | 혈관형성 조절제로서의 피리미딘아민 |
| EE05715B1 (et) | 2001-01-05 | 2014-06-16 | Pfizer Inc. | Antikehad insuliinitaolise kasvufaktori I retseptorile |
| US6699866B2 (en) | 2001-04-17 | 2004-03-02 | Sepracor Inc. | Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof |
| AU2002345792A1 (en) | 2001-06-21 | 2003-01-08 | Pfizer Inc. | Thienopyridine and thienopyrimidine anticancer agents |
| HN2002000156A (es) | 2001-07-06 | 2003-11-27 | Inc Agouron Pharmaceuticals | Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización. |
| US7265134B2 (en) | 2001-08-17 | 2007-09-04 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US20030143165A1 (en) * | 2002-01-25 | 2003-07-31 | Allan Evans | NSAID-containing topical formulations that demonstrate chemopreventive activity |
| AU2003210969A1 (en) * | 2002-02-11 | 2003-09-04 | Bayer Corporation | Aryl ureas with raf kinase and angiogenesis inhibiting activity |
| AU2003209116A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
| AU2003209119A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
| US7125888B2 (en) | 2002-05-02 | 2006-10-24 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6989451B2 (en) * | 2002-06-04 | 2006-01-24 | Valeant Research & Development | Heterocyclic compounds and uses thereof |
| AU2003232551A1 (en) * | 2002-06-13 | 2003-12-31 | Qlt Inc. | Methods of using isothiazole derivatives to treat cancer or inflammation |
| CA2488642C (en) | 2002-06-27 | 2011-09-06 | Dharma Rao Polisetti | Aryl carbonyl derivatives as glucokinase activators |
| WO2004011461A1 (en) * | 2002-07-25 | 2004-02-05 | Pfizer Products Inc. | Isothiazole derivatives useful as anticancer agents |
| US7498349B2 (en) | 2002-08-02 | 2009-03-03 | Genesoft Pharmaceuticals, Inc. | Biaryl compounds having anti-infective activity |
| AP2005003232A0 (en) * | 2002-08-19 | 2005-03-31 | Pfizer Prod Inc | Combination therapy for hyperproliferative diseases. |
| WO2004039318A2 (en) | 2002-10-25 | 2004-05-13 | Genesoft Pharmaceuticals, Inc. | Anti-infective biaryl compounds |
| EP1587529A4 (en) | 2002-12-10 | 2009-08-12 | Oscient Pharmaceuticals Corp | ANTIBACTERIAL COMPOUNDS WITH (PYROCARBOXAMIDE) - (BENZAMID) - (IMIDAZOLE CARBOXAMIDE) MOTIVE |
| DK1585743T3 (da) | 2002-12-19 | 2007-09-17 | Pfizer | 2-(H-indazol-6-ylamino)-benzamid forbindelser som protein kinase inhibitorer, nyttige til behandling opthalmiske sygdomme |
| BRPI0407055A (pt) * | 2003-01-27 | 2006-01-17 | Pfizer Prod Inc | Derivados de isotiazol |
| US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| CA2523426C (en) * | 2003-04-24 | 2013-02-26 | Incyte Corporation | Aza spiro alkane derivatives as inhibitors of metalloproteases |
| ES2288694T3 (es) | 2003-05-20 | 2008-01-16 | Bayer Pharmaceuticals Corporation | Diaril ureas para enfermedades mediadas por el receptor del factor de crecimiento derivado de plaquetas. |
| EP1648998B1 (en) | 2003-07-18 | 2014-10-01 | Amgen Inc. | Specific binding agents to hepatocyte growth factor |
| UA84156C2 (ru) | 2003-07-23 | 2008-09-25 | Байер Фармасьютикалс Корпорейшн | Фторозамещённая омега-карбоксиарилдифенилмочевина для лечения и профилактики болезней и состояний |
| HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| CN100450998C (zh) | 2003-11-11 | 2009-01-14 | 卫材R&D管理有限公司 | 脲衍生物的制备方法 |
| SI1723128T1 (sl) | 2004-01-06 | 2013-04-30 | Transtech Pharma, Inc. | Heteroaril uree in njihova uporaba kot aktivatorji glukokinaze |
| ES2246687B2 (es) * | 2004-02-11 | 2006-11-16 | Miguel Muñoz Saez | Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales. |
| WO2005081997A2 (en) * | 2004-02-20 | 2005-09-09 | The Scripps Research Institute | Isothiazole based protein kinase inhibitors |
| WO2005102327A1 (en) * | 2004-04-20 | 2005-11-03 | Pfizer Products Inc. | Dosage forms and methods of treatment using vegfr inhibitors |
| EP2295426A1 (en) | 2004-04-30 | 2011-03-16 | Bayer HealthCare, LLC | Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
| TW200538104A (en) * | 2004-05-17 | 2005-12-01 | Pfizer Prod Inc | Phenyl derivatives for the treatment of abnormal cell growth |
| MX2007000610A (es) | 2004-07-16 | 2007-03-07 | Pfizer Prod Inc | Tratamiento de combinacion para enfermedades malignas no hematologicas usando un anti-cuerpo de receptor de factor i de crecimiento de tipo anti-insulina. |
| MX2007002312A (es) | 2004-08-26 | 2007-04-16 | Pfizer | Compuestos de aminoheteroarilo enantiomericamente puros como inhibidores de proteina quinasa. |
| PT1784183E (pt) | 2004-08-26 | 2012-03-09 | Pfizer | Processos para a preparação de derivados de isotiazole |
| US8772269B2 (en) | 2004-09-13 | 2014-07-08 | Eisai R&D Management Co., Ltd. | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors |
| WO2006030941A1 (ja) | 2004-09-13 | 2006-03-23 | Eisai R & D Management Co., Ltd. | スルホンアミド含有化合物の血管新生阻害物質との併用 |
| ATE428421T1 (de) | 2004-09-17 | 2009-05-15 | Eisai R&D Man Co Ltd | Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften |
| CA2587642C (en) | 2004-11-30 | 2013-04-09 | Amgen Inc. | Substituted heterocycles and methods of use |
| US7429667B2 (en) | 2005-01-20 | 2008-09-30 | Ardea Biosciences, Inc. | Phenylamino isothiazole carboxamidines as MEK inhibitors |
| US8093011B2 (en) | 2005-03-16 | 2012-01-10 | Haley John D | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| US20060216288A1 (en) * | 2005-03-22 | 2006-09-28 | Amgen Inc | Combinations for the treatment of cancer |
| RU2413735C2 (ru) | 2005-03-31 | 2011-03-10 | Эдженсис, Инк. | Антитела и родственные молекулы, связывающиеся с белками 161p2f10b |
| EP2444421A1 (en) | 2005-04-26 | 2012-04-25 | Pfizer Inc. | P-Cadherin antibodies |
| EP1904466A1 (en) | 2005-07-08 | 2008-04-02 | Novo Nordisk A/S | Dicycloalkyl urea glucokinase activators |
| EP2281901B1 (en) | 2005-08-02 | 2013-11-27 | Eisai R&D Management Co., Ltd. | Anti-tumour pharmaceutical composition with angiogenesis inhibitors |
| GEP20125398B (en) | 2005-09-07 | 2012-02-27 | Amjen Freemont Ink | Human monoclonal antibodies to activin receptor-like kinase-1 |
| CA2623125A1 (en) | 2005-09-20 | 2007-03-29 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| US20080108664A1 (en) | 2005-12-23 | 2008-05-08 | Liu Belle B | Solid-state form of AMG 706 and pharmaceutical compositions thereof |
| AR059066A1 (es) * | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| WO2007092178A1 (en) * | 2006-02-10 | 2007-08-16 | Amgen Inc. | Hydrate forms of amg706 |
| WO2007121269A2 (en) | 2006-04-11 | 2007-10-25 | Ardea Biosciences, Inc. | N-aryl-n'alkyl sulfamides as mek inhibitors |
| MX2008013097A (es) * | 2006-04-18 | 2008-10-27 | Ardea Biosciences Inc | Piridona sulfonamidas y piridona sulfamidas como inhibidores de metiletilcetona. |
| CN101490046A (zh) | 2006-05-09 | 2009-07-22 | 辉瑞产品公司 | 环烷基氨基酸衍生物及其药物组合物 |
| ES2556173T3 (es) | 2006-05-18 | 2016-01-13 | Eisai R&D Management Co., Ltd. | Agente antitumoral para un cáncer de tiroides |
| US7910108B2 (en) * | 2006-06-05 | 2011-03-22 | Incyte Corporation | Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases |
| UA95480C2 (uk) * | 2006-06-08 | 2011-08-10 | Елі Ліллі Енд Компані | Заміщені карбоксаміди |
| US7932390B2 (en) | 2006-06-29 | 2011-04-26 | Hoffman-La Roche Inc. | Substituted thieno[3,2-C]pyridine carboxylic acid derivatives |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| CN101511793B (zh) | 2006-08-28 | 2011-08-03 | 卫材R&D管理有限公司 | 针对未分化型胃癌的抗肿瘤剂 |
| US7687522B2 (en) | 2006-12-20 | 2010-03-30 | Amgen Inc. | Substituted pyridines and pyrimidines and their use in treatment of cancer |
| AU2008205252B2 (en) | 2007-01-09 | 2013-02-21 | Amgen Inc. | Bis-aryl amide derivatives useful for the treatment of cancer |
| CN101600694A (zh) | 2007-01-29 | 2009-12-09 | 卫材R&D管理有限公司 | 未分化型胃癌治疗用组合物 |
| AU2008219166B2 (en) | 2007-02-16 | 2013-05-16 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors |
| ES2396741T3 (es) * | 2007-02-26 | 2013-02-25 | Santen Pharmaceutical Co., Ltd | Nuevo derivado de pirrol que tiene un grupo ureído y un grupo aminocarbonilo como sustituyentes |
| CA2683559C (en) | 2007-04-13 | 2019-09-24 | Dana Farber Cancer Institute, Inc. | Methods for treating cancer resistant to erbb therapeutics |
| EP2137535B1 (en) * | 2007-04-13 | 2015-06-03 | Dana-Farber Cancer Institute, Inc. | Receptor tyrosine kinase profiling |
| US8509487B2 (en) * | 2007-04-19 | 2013-08-13 | Avago Technologies General Ip (Singapore) Pte. Ltd. | System and method for optically measuring a parameter of an object |
| MX2010001636A (es) | 2007-08-14 | 2010-03-15 | Hoffmann La Roche | Derivados de pirazolo[3,4-d]-pirimidina como agentes antiproliferativos. |
| EP3330292A1 (en) | 2007-08-21 | 2018-06-06 | Amgen, Inc | Human c-fms antigen binding proteins |
| EP2218712B1 (en) | 2007-11-09 | 2015-07-01 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
| US20100029491A1 (en) * | 2008-07-11 | 2010-02-04 | Maike Schmidt | Methods and compositions for diagnostic use for tumor treatment |
| CA2746120A1 (en) | 2008-12-23 | 2010-07-01 | Genentech, Inc. | Methods and compositions for diagnostic use in cancer patients |
| US20120189641A1 (en) | 2009-02-25 | 2012-07-26 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| JP2012519170A (ja) | 2009-02-26 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ，エルエルシー | 生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法 |
| EP2401613A2 (en) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| EP2401614A1 (en) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| NZ594343A (en) | 2009-03-25 | 2013-10-25 | Genentech Inc | Novel anti-alpha5beta1 antibodies and uses thereof |
| WO2011008696A2 (en) | 2009-07-13 | 2011-01-20 | Genentech, Inc. | Diagnostic methods and compositions for treatment of cancer |
| EP2459191A1 (en) | 2009-07-31 | 2012-06-06 | OSI Pharmaceuticals, LLC | Mtor inhibitor and angiogenesis inhibitor combination therapy |
| JP5606537B2 (ja) | 2009-09-17 | 2014-10-15 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 癌患者における診断使用のための方法及び組成物 |
| WO2011073521A1 (en) | 2009-12-15 | 2011-06-23 | Petri Salven | Methods for enriching adult-derived endothelial progenitor cells and uses thereof |
| CN107095846A (zh) | 2009-12-21 | 2017-08-29 | 霍夫曼-拉罗奇有限公司 | 抗体配制剂 |
| ES2753748T3 (es) | 2010-02-12 | 2020-04-14 | Pfizer | Sales y polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6H-azepino[5,4,3-cd]indol-6-ona |
| JP2013527748A (ja) | 2010-03-03 | 2013-07-04 | オーエスアイ・ファーマシューティカルズ，エルエルシー | インスリン様増殖因子１受容体キナーゼ阻害剤に対する抗癌反応の予測に役立つ生物学的マーカー |
| EP2542893A2 (en) | 2010-03-03 | 2013-01-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| WO2011153224A2 (en) | 2010-06-02 | 2011-12-08 | Genentech, Inc. | Diagnostic methods and compositions for treatment of cancer |
| CN103068851B (zh) | 2010-06-16 | 2015-03-11 | 高等教育联邦系统-匹兹堡大学 | 内质蛋白的抗体及其用途 |
| WO2011161217A2 (en) | 2010-06-23 | 2011-12-29 | Palacký University in Olomouc | Targeting of vegfr2 |
| AU2011270165B2 (en) | 2010-06-25 | 2015-12-24 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
| SG187592A1 (en) | 2010-07-23 | 2013-03-28 | Univ Boston | Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery |
| WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
| US20120214830A1 (en) | 2011-02-22 | 2012-08-23 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
| GB201103578D0 (en) | 2011-03-02 | 2011-04-13 | Sabrepharm Ltd | Dipyridinium derivatives |
| UA112539C2 (uk) | 2011-03-03 | 2016-09-26 | Новартіс Аг | Спосіб одержання похідних 2-карбоксамідциклоаміносечовини |
| PT2688887E (pt) | 2011-03-23 | 2015-07-06 | Amgen Inc | Inibidores duais tricíclicos fusionados de cdk 4/6 e flt3 |
| KR101762999B1 (ko) | 2011-04-18 | 2017-07-28 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 종양 치료제 |
| WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
| US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| US9416132B2 (en) | 2011-07-21 | 2016-08-16 | Tolero Pharmaceuticals, Inc. | Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors |
| US9745288B2 (en) | 2011-08-16 | 2017-08-29 | Indiana University Research And Technology Corporation | Compounds and methods for treating cancer by inhibiting the urokinase receptor |
| EP3184525B1 (en) | 2011-12-28 | 2020-10-28 | Allergan, Inc. | 3-phenyl-5-ureidoisothiazole-4-carboxamide derivatives as kinase inhibitors |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| CN103508961B (zh) | 2012-06-26 | 2015-07-22 | 中美冠科生物技术（太仓）有限公司 | 抗肿瘤药物 |
| US9505749B2 (en) | 2012-08-29 | 2016-11-29 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
| EP2909181B1 (en) | 2012-10-16 | 2017-08-09 | Tolero Pharmaceuticals, Inc. | Pkm2 modulators and methods for their use |
| WO2014098176A1 (ja) | 2012-12-21 | 2014-06-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体のアモルファス及びその製造方法 |
| RU2019120404A (ru) | 2013-03-13 | 2019-08-06 | Дженентек, Инк. | Составы антител |
| CA2905993C (en) | 2013-03-14 | 2022-12-06 | Tolero Pharmaceuticals, Inc. | Substituted 4-amino-pyrimidinyl-2-amino-phenyl derivatives and pharmaceutical compositions thereof for use as jak2 and alk2 inhibitors |
| RU2665953C2 (ru) | 2013-03-14 | 2018-09-05 | Паноптика, Инк. | Офтальмологические составы для доставки лекарственных средств к заднему сегменту глаза |
| SG11201509278XA (en) | 2013-05-14 | 2015-12-30 | Eisai R&D Man Co Ltd | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| CN111808957A (zh) | 2014-04-04 | 2020-10-23 | 中美冠科生物技术（太仓）有限公司 | 用于确定对mek/erk抑制剂的应答性的方法 |
| PL3524595T3 (pl) | 2014-08-28 | 2022-10-31 | Eisai R&D Management Co., Ltd. | Pochodna chinoliny o wysokiej czystości i sposób jej wytwarzania |
| EP3193932B1 (en) | 2014-09-15 | 2023-04-26 | F. Hoffmann-La Roche AG | Antibody formulations |
| PT3193867T (pt) | 2014-09-17 | 2021-03-09 | Panoptica Inc | Formulações oculares para administração de fármaco e proteção do segmento anterior do olho |
| US9353093B2 (en) | 2014-10-07 | 2016-05-31 | Allergan, Inc. | Indole-1-carboxamides as kinase inhibitors |
| US9403803B2 (en) | 2014-10-08 | 2016-08-02 | Allergan, Inc. | Indole-3-carboxamides as kinase inhibitors |
| US9371314B2 (en) | 2014-10-09 | 2016-06-21 | Allergan, Inc. | Pyridyl benzothiophenes as kinase inhibitors |
| US9359336B2 (en) | 2014-10-09 | 2016-06-07 | Allergan, Inc. | Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors |
| WO2016097918A1 (en) | 2014-12-18 | 2016-06-23 | Pfizer Inc. | Pyrimidine and triazine derivatives and their use as axl inhibitors |
| HK1247955A1 (zh) | 2015-01-08 | 2018-10-05 | 小利兰.斯坦福大学托管委员会 | 提供骨、骨髓及软骨的诱导的因子和细胞 |
| HUE064614T2 (hu) | 2015-02-25 | 2024-04-28 | Eisai R&D Man Co Ltd | Eljárás egy kinolin-származék keserû ízének elnyomására |
| WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
| EP3611506B1 (en) | 2015-04-20 | 2021-11-17 | Sumitomo Dainippon Pharma Oncology, Inc. | Predicting response to alvocidib by mitochondrial profiling |
| AU2016264212B2 (en) | 2015-05-18 | 2020-10-22 | Sumitomo Pharma Oncology, Inc. | Alvocidib prodrugs having increased bioavailability |
| ES2886107T3 (es) | 2015-06-16 | 2021-12-16 | Prism Biolab Co Ltd | Antineoplásico |
| RU2759963C2 (ru) | 2015-08-03 | 2021-11-19 | Сумитомо Даиниппон Фарма Онколоджи, Инк. | Комбинированные терапии для лечения рака |
| US12220398B2 (en) | 2015-08-20 | 2025-02-11 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
| GB2543550A (en) | 2015-10-21 | 2017-04-26 | Hox Therapeutics Ltd | Peptides |
| KR20180100125A (ko) | 2015-12-03 | 2018-09-07 | 아지오스 파마슈티컬스 아이엔씨. | Mtap 널 암을 치료하기 위한 mat2a 억제제 |
| WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| KR20190099260A (ko) | 2016-12-19 | 2019-08-26 | 톨레로 파마수티컬스, 인크. | 프로파일링 펩티드 및 감도 프로파일링을 위한 방법 |
| US10532042B2 (en) | 2016-12-22 | 2020-01-14 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| KR102539920B1 (ko) | 2017-02-08 | 2023-06-05 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 종양-치료용 약제학적 조성물 |
| CA3061888A1 (en) | 2017-05-16 | 2018-11-22 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| EP4403175A3 (en) | 2017-09-08 | 2024-10-02 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
| US11497756B2 (en) | 2017-09-12 | 2022-11-15 | Sumitomo Pharma Oncology, Inc. | Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib |
| JP7361722B2 (ja) | 2018-05-04 | 2023-10-16 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤及び同一物の使用方法 |
| MA52501A (fr) | 2018-05-04 | 2021-03-10 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| WO2019217691A1 (en) | 2018-05-10 | 2019-11-14 | Amgen Inc. | Kras g12c inhibitors for the treatment of cancer |
| CA3098885A1 (en) | 2018-06-01 | 2019-12-05 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| EP3802537A1 (en) | 2018-06-11 | 2021-04-14 | Amgen Inc. | Kras g12c inhibitors for treating cancer |
| US11285156B2 (en) | 2018-06-12 | 2022-03-29 | Amgen Inc. | Substituted piperazines as KRAS G12C inhibitors |
| EP4487909A3 (en) | 2018-06-12 | 2025-03-19 | vTv Therapeutics LLC | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
| US11040038B2 (en) | 2018-07-26 | 2021-06-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same |
| JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法 |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| EP3883565A1 (en) | 2018-11-19 | 2021-09-29 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| KR20210099066A (ko) | 2018-12-04 | 2021-08-11 | 스미토모 다이니폰 파마 온콜로지, 인크. | 암의 치료를 위한 작용제로서 사용하기 위한 cdk9 억제제 및 그의 다형체 |
| JP7212781B2 (ja) | 2018-12-19 | 2023-01-25 | ディスアーム セラピューティクス， インコーポレイテッド | 神経保護剤と組み合わせたｓａｒｍ１の阻害剤 |
| WO2020132649A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
| EP3898592B1 (en) | 2018-12-20 | 2024-10-09 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
| JP7407196B2 (ja) | 2018-12-20 | 2023-12-28 | アムジエン・インコーポレーテツド | Ｋｉｆ１８ａ阻害剤 |
| CA3123042A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
| WO2020167990A1 (en) | 2019-02-12 | 2020-08-20 | Tolero Pharmaceuticals, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
| EP3931195A1 (en) | 2019-03-01 | 2022-01-05 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
| CN113727758A (zh) | 2019-03-01 | 2021-11-30 | 锐新医药公司 | 双环杂环基化合物及其用途 |
| US11793802B2 (en) | 2019-03-20 | 2023-10-24 | Sumitomo Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (AML) with venetoclax failure |
| MX2021011289A (es) | 2019-03-22 | 2021-11-03 | Sumitomo Pharma Oncology Inc | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| CR20210665A (es) | 2019-05-21 | 2022-01-25 | Amgen Inc | Formas en estado sólido |
| JP7699100B2 (ja) | 2019-08-02 | 2025-06-26 | アムジエン・インコーポレーテツド | Ｋｉｆ１８ａ阻害剤 |
| EP4007752B1 (en) | 2019-08-02 | 2025-09-24 | Amgen Inc. | Kif18a inhibitors |
| US20220372018A1 (en) | 2019-08-02 | 2022-11-24 | Amgen Inc. | Kif18a inhibitors |
| EP4007756A1 (en) | 2019-08-02 | 2022-06-08 | Amgen Inc. | Kif18a inhibitors |
| WO2021081212A1 (en) | 2019-10-24 | 2021-04-29 | Amgen Inc. | Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer |
| EP4054719A1 (en) | 2019-11-04 | 2022-09-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2021091967A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| AU2020377925A1 (en) | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
| MX2022005525A (es) | 2019-11-08 | 2022-06-08 | Revolution Medicines Inc | Compuestos de heteroarilo bicíclicos y usos de estos. |
| EP4058432A1 (en) | 2019-11-14 | 2022-09-21 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
| CN120463705A (zh) | 2019-11-14 | 2025-08-12 | 美国安进公司 | Kras g12c抑制剂化合物的改善的合成 |
| JP2023505100A (ja) | 2019-11-27 | 2023-02-08 | レボリューション メディシンズ インコーポレイテッド | 共有ｒａｓ阻害剤及びその使用 |
| TW202140011A (zh) | 2020-01-07 | 2021-11-01 | 美商銳新醫藥公司 | Shp2抑制劑給藥和治療癌症的方法 |
| WO2021155006A1 (en) | 2020-01-31 | 2021-08-05 | Les Laboratoires Servier Sas | Inhibitors of cyclin-dependent kinases and uses thereof |
| WO2021167840A1 (en) | 2020-02-18 | 2021-08-26 | Vtv Therapeutics Llc | Sulfoxide and sulfone glucokinase activators and methods of use thereof |
| CA3187757A1 (en) | 2020-09-03 | 2022-03-24 | Ethan AHLER | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
| CN117396472A (zh) | 2020-12-22 | 2024-01-12 | 上海齐鲁锐格医药研发有限公司 | Sos1抑制剂及其用途 |
| AR125782A1 (es) | 2021-05-05 | 2023-08-16 | Revolution Medicines Inc | Inhibidores de ras |
| CN118852330A (zh) | 2021-05-05 | 2024-10-29 | 锐新医药公司 | 用于治疗癌症的ras抑制剂 |
| JP2024516450A (ja) | 2021-05-05 | 2024-04-15 | レボリューション メディシンズ インコーポレイテッド | 共有結合性ｒａｓ阻害剤及びその使用 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| KR20240156373A (ko) | 2022-03-07 | 2024-10-29 | 암젠 인크 | 4-메틸-2-프로판-2-일-피리딘-3-카르보니트릴의 제조 방법 |
| CN119136806A (zh) | 2022-03-08 | 2024-12-13 | 锐新医药公司 | 用于治疗免疫难治性肺癌的方法 |
| IL317476A (en) | 2022-06-10 | 2025-02-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| IL320217A (en) | 2022-10-14 | 2025-06-01 | Black Diamond Therapeutics Inc | Methods for treating cancer using isoquinoline or 6-azaquinoline derivatives |
| TWI894754B (zh) * | 2022-12-28 | 2025-08-21 | 大陸商蘇州必揚醫藥科技有限公司 | 一種蛋白酪胺酸激酶抑制劑及其醫藥用途 |
| TW202504611A (zh) | 2023-03-30 | 2025-02-01 | 美商銳新醫藥公司 | 用於誘導ｒａｓ ｇｔｐ水解之組合物及其用途 |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| US20240352036A1 (en) | 2023-04-14 | 2024-10-24 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| WO2024216048A1 (en) | 2023-04-14 | 2024-10-17 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025137507A1 (en) | 2023-12-22 | 2025-06-26 | Regor Pharmaceuticals, Inc. | Sos1 inhibitors and uses thereof |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4059433A (en) * | 1976-06-18 | 1977-11-22 | Fmc Corporation | 3-Alkoxyisothiazole derivatives as herbicides |
| US4057416A (en) * | 1976-06-18 | 1977-11-08 | Fmc Corporation | 3-Alkylthio-, 3-alkylsulfinyl-, and 3-alkylsulfonylisothiazole derivatives as herbicides |
| SG64322A1 (en) | 1991-05-10 | 1999-04-27 | Rhone Poulenc Rorer Int | Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
| MY109202A (en) | 1992-07-10 | 1996-12-31 | Nihon Nohyaku Co Ltd | Isothiazole derivatives and processes for preparing the same as well as termite controlling agents comprising the same as active ingredient |
| US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| IL112721A0 (en) | 1994-03-10 | 1995-05-26 | Zeneca Ltd | Azole derivatives |
| DE4425642A1 (de) * | 1994-07-20 | 1996-01-25 | Merck Patent Gmbh | Partiell fluorierte Benzolderivate |
| ES2256968T3 (es) | 1997-10-27 | 2006-07-16 | Agouron Pharmaceuticals, Inc. | Derivados de 4-aminotiazol, su preparacion y su uso como inhibidores de quinasas dependientes de ciclina. |
| UA60365C2 (uk) * | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
| MXPA03004714A (es) * | 2000-11-28 | 2003-08-19 | Pfizer Prod Inc | Sales de una isotiazol-4-carboxamida y su uso como agentes de antihiperproliferacion. |
| BRPI0407055A (pt) * | 2003-01-27 | 2006-01-17 | Pfizer Prod Inc | Derivados de isotiazol |
-
1999
- 1999-03-05 UA UA2000126916A patent/UA60365C2/uk unknown
- 1999-05-03 TR TR2000/03478T patent/TR200003478T2/xx unknown
- 1999-05-03 NZ NZ507009A patent/NZ507009A/en not_active IP Right Cessation
- 1999-05-03 CN CNA2004100769265A patent/CN1616386A/zh active Pending
- 1999-05-03 JP JP2000552102A patent/JP3735254B2/ja not_active Expired - Lifetime
- 1999-05-03 PL PL344691A patent/PL198151B1/pl not_active IP Right Cessation
- 1999-05-03 CZ CZ20004451A patent/CZ298559B6/cs not_active IP Right Cessation
- 1999-05-03 ES ES99914724T patent/ES2226368T3/es not_active Expired - Lifetime
- 1999-05-03 BR BRPI9910900-0B1A patent/BR9910900B1/pt not_active IP Right Cessation
- 1999-05-03 SK SK1778-2000A patent/SK286405B6/sk not_active IP Right Cessation
- 1999-05-03 KR KR10-2000-7013656A patent/KR100392434B1/ko not_active Expired - Lifetime
- 1999-05-03 HR HR20000835A patent/HRP20000835B1/xx not_active IP Right Cessation
- 1999-05-03 EP EP99914724A patent/EP1084114B1/en not_active Expired - Lifetime
- 1999-05-03 HU HU0102422A patent/HUP0102422A3/hu unknown
- 1999-05-03 PT PT99914724T patent/PT1084114E/pt unknown
- 1999-05-03 CA CA002475113A patent/CA2475113C/en not_active Expired - Lifetime
- 1999-05-03 ID IDW20002528A patent/ID27006A/id unknown
- 1999-05-03 AU AU33421/99A patent/AU3342199A/en not_active Abandoned
- 1999-05-03 YU YU70100A patent/YU70100A/sh unknown
- 1999-05-03 IL IL13877699A patent/IL138776A0/xx not_active IP Right Cessation
- 1999-05-03 WO PCT/IB1999/000797 patent/WO1999062890A1/en not_active Ceased
- 1999-05-03 AT AT99914724T patent/ATE275553T1/de active
- 1999-05-03 DE DE69920009T patent/DE69920009T2/de not_active Expired - Lifetime
- 1999-05-03 SI SI9930661T patent/SI1084114T1/xx unknown
- 1999-05-03 EA EA200001146A patent/EA004935B1/ru not_active IP Right Cessation
- 1999-05-03 CN CNB998068373A patent/CN1172918C/zh not_active Expired - Lifetime
- 1999-05-03 CA CA002333703A patent/CA2333703C/en not_active Expired - Lifetime
- 1999-05-11 PA PA19998472301A patent/PA8472301A1/es unknown
- 1999-05-20 GT GT199900070A patent/GT199900070A/es unknown
- 1999-05-21 US US09/316,837 patent/US6235764B1/en not_active Expired - Lifetime
- 1999-05-26 HN HN1999000080A patent/HN1999000080A/es unknown
- 1999-05-31 TW TW088108991A patent/TW561154B/zh not_active IP Right Cessation
- 1999-06-01 PE PE1999000463A patent/PE20000568A1/es not_active Application Discontinuation
- 1999-06-02 MY MYPI99002208A patent/MY130668A/en unknown
- 1999-06-02 AR ARP990102607A patent/AR016725A1/es active IP Right Grant
- 1999-06-02 TN TNTNSN99106A patent/TNSN99106A1/fr unknown
- 1999-06-02 MA MA25605A patent/MA26638A1/fr unknown
- 1999-06-02 SA SA99200217A patent/SA99200217B1/ar unknown
- 1999-06-03 CO CO99034996A patent/CO5011121A1/es unknown
- 1999-06-03 ZA ZA9903752A patent/ZA993752B/xx unknown
- 1999-06-03 AP APAP/P/1999/001560A patent/AP1309A/en active
- 1999-07-21 UY UY25619A patent/UY25619A1/es not_active Application Discontinuation
-
2000
- 2000-10-20 OA OA1200000289A patent/OA11504A/en unknown
- 2000-10-27 IS IS5690A patent/IS2269B/is unknown
- 2000-11-28 BG BG104998A patent/BG65104B1/bg unknown
- 2000-11-30 NO NO20006071A patent/NO318798B1/no not_active IP Right Cessation
-
2001
- 2001-03-09 US US09/803,296 patent/US6548526B2/en not_active Expired - Lifetime
-
2003
- 2003-02-03 US US10/357,093 patent/US7405218B2/en not_active Expired - Fee Related
-
2004
- 2004-07-16 JP JP2004209396A patent/JP2005002122A/ja active Pending
-
2007
- 2007-08-08 GE GEAP200710221A patent/GEP20084337B/en unknown
-
2008
- 2008-07-29 US US12/181,803 patent/US7790902B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2475113C (en) | Isothiazole derivatives useful as anticancer agents | |
| DE60113283T2 (de) | Thiadiazole und oxadiazole sowie ihre verwendung als phosphodiesterase-7 inhibitoren | |
| US6380214B1 (en) | Heterocyclic derivatives useful as anticancer agents | |
| CN101043888B (zh) | 制备异噻唑衍生物的方法 | |
| AU2004202433B2 (en) | Isothiazole Derivatives Useful as Anticancer Agents | |
| MXPA00011849A (en) | Isothiazole derivatives useful as anticancer agents | |
| AU2007203344A1 (en) | Isothiazole derivatives useful as anticancer agents | |
| US3322768A (en) | Aralkyl piperazines and salts thereof | |
| US6156761A (en) | Substituted tetralone derivatives for enhancing cognition | |
| US3639610A (en) | Controlling nematodes with n-car-bamyl-2-imino-1 3-oxathiolanes | |
| JPH01238529A (ja) | 骨粗鬆症予防治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20190503 |